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ABSTRACT OF DISSERTATION

BIOLOGICAL, BEHAVIORAL, AND PSYCHOSOCIAL ATTRIBUTES OF
INDIVIDUALS WITH COPD

The purpose of this dissertation was to evaluate the biological, behavioral, and
psychosocial attributes of individuals diagnosed with chronic obstructive pulmonary
disease (COPD). Specific aims were to: 1) explore the predictive power of spirometry
measures for event-free survival in patients with heart failure and suspected COPD,
focusing on the differences in survival between those with and without airflow limitation;
2) examine the psychometric properties of the Multidimensional Scale of Perceived
Social Support (MSPSS) in patients with concomitant COPD and heart failure; and 3) test
the efficacy of a theory-based, multidimensional, self-care educational intervention using
an eHealth platform on measures of symptom severity and variability, anxiety and
depressive symptoms, perceived self-care ability, perceived self-care adherence, and selfcare information needs (knowledge) in a sample of adult patients with stable COPD.
Specific aim one was addressed by evaluation of the predictive power of
spirometry measures (forced expiratory volume/second [FEV1], forced vital capacity
[FVC], and the ratio of FEV1/FVC) for event-free time to combined
hospitalization/mortality after controlling for clinical and sociodemographic variables.
This analysis revealed that those patients with airflow limitation were 2.2 times more
likely to experience hospitalization/mortality compared to those without airflow
limitation. The second specific aim was addressed with a psychometric evaluation of the
Multidimensional Scale of Perceived Social support (MSPSS) which included
determination of internal consistency reliability, the factor structure and construct validity
by hypothesis testing in participants with comorbid COPD and heart failure. The MSPSS
was a valid and reliable instrument to measure perceived social support in patients with
comorbid COPD and heart failure. The third specific aim was addressed by a trial of an
eHealth educational intervention in participants with COPD (N = 20). This intervention
resulted in significant change in symptom severity evaluation in patients categorized as
having medium symptom severity for the following symptoms: distress due to cough,

chest tightness, dyspnea with activity and fatigue; these symptoms were perceived as
more severe in the intervention period. Anxiety, depressive symptoms and perceived selfcare ability were unchanged; however, perceived self-care adherence scores improved,
and knowledge needs were significantly reduced after the intervention.
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CHAPTER ONE
Introduction
Chronic obstructive pulmonary disease (COPD) is predicted to be the third
leading cause of death worldwide by 2030.1 In the United States, 15 to 22 million people
are currently diagnosed with COPD; the deaths from COPD are estimated to rise 30% in
the next 10 years. 2,3 This disease is progressive, irreversible and characterized by
persistent airflow limitation and respiratory symptoms.4 As COPD progresses, symptoms
often become more severe, physical and psychological responses are elicited, and risk for
hospitalization increases. Breathlessness or dyspnea is the most common symptom
reported by those with COPD, followed by cough, troublesome mucous, wheezing, and
chest tightness.5-10 Furthermore, approximately 40% of patients with COPD have clinical
anxiety, and approximately 25% experience clinically significant depressive
symptoms.11,12 Due to the high symptom burden and progressive nature of COPD, it is
necessary for patients to perform a variety of self-care activities to maintain homeostasis.
Self-care is defined as the process by which individuals with chronic disease
attain optimal health through learned, intentional actions that include symptom
recognition and response, adherence to prescribed treatment and medications, intentional
lifestyle alterations, regular interaction with health care professionals, and evaluation of
these actions.13 The increased incidence and prevalence of COPD has been the impetus
for the development of education and training programs focused on development of
effective self-care behaviors; these structured, and multi-faceted interventions aimed to
educate, motivate, engage, and support patients to adapt their health behaviors and
develop skills to provide relief of symptoms, slow the progression of disease, improve
1

physical functioning, improve health related quality of life and prevent exacerbations that
require hospitalization. 4,14-17 Effective self-care for patients with COPD improved
health-related quality of life (HRQoL),15,18 reduced dyspnea,19 decreased risk for allcause hospitalization,19-21 and reduced anxiety and depressive symptoms.22,23 However,
only 40% of patients with COPD demonstrate prolonged retention of self-care
behaviors.24
Consequences of poor self-care behaviors may result in quicker disease
progression, increased morbidity and premature mortality; patients with COPD have an
average life expectancy of 5.8 years less than age-adjusted healthy controls and are at
70% to 90% increase likelihood of death if they have comorbid cardiovascular
disease.19,25,26 However, self-care is a still a relatively new concept that has been
understudied in this population. There is currently no consensus as to what constitutes
appropriate self-care behaviors for patients with COPD; self-care behaviors taught to
patients often vary from practitioner to practitioner,19,27 may not be evidence-based, and
the patient’s pre-existing self-care abilities are not always taken into consideration.13
Furthermore, studying patient self-care is particularly challenging in that patients spend a
majority of time away from the healthcare setting, and researchers are often reliant on
periodic self-reports of patient subjective assessment of disease-state. Although there is a
lack of research outlining standardized self-care recommendations, the consequences of
performing self-care are clear; it is imperative that researchers develop and test
standardized self-care interventions to promote sustainable self-care behaviors
Traditionally, researchers used objective measures to gauge self-care efficacy and
only recently have researchers begun to study the effects of self-care behaviors on
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subjective outcomes such as HRQoL, perceived treatment adherence, perceived self-care
ability and anxiety/depressive symptoms.19,21 Previous investigators concluded effective
self-care for patients with COPD increased HRQOL by 5% – 6.5%15,18 and reduced
anxiety and depression scores by an average of 2.7% to 18.4%.22,23,28 Moreover, findings
and conclusions from a recent Cochrane review examining the benefits of self-care
behaviors on outcomes further supported the effectiveness of self-care on outcomes such
as HRQoL, anxiety, mortality and hospitalizations.19 Zwerink and colleagues concluded
that the self-care interventions were effective at improving outcomes, however these
investigators could not conclude which self-care behaviors were best at improving
outcomes; tested self-care interventions were too heterogeneous.19 Although desirable
outcomes resulted after implementing self-care interventions, there is a lack of evidence
to support which interventions should be taught to patients with COPD; this reflects the
current state of the science in self-care for patients with COPD. Additionally, there are
limited research studies that evaluated the relationships between self-care and other key
outcomes such as symptom burden, psychological distress, perceived treatment
adherence, perceived self-care ability and self-care information needs (knowledge) in
patients with COPD. Therefore, the purpose of this dissertation was to evaluate the
relationship between the biological, psychosocial and behavioral self-care attributes on
outcomes in individuals with COPD.
Patients with comorbid COPD and heart failure share numerous commonalities
such as the age of the affected population, cigarette smoking as a risk factor, presence of
systemic inflammation, periodic episodes of disease exacerbation that require
hospitalization, and dyspnea as a prominent symptom.29 Up to one third of patients
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diagnosed with heart failure (HF) exhibit some degree of COPD, and approximately 40%
of patients diagnosed with COPD have heart disease.30,31 Despite the high prevalence of
comorbid disease and similarities in clinical presentation, the relationship of airflow
limitation and combined all-cause hospitalization/mortality has not been explored in
patients with heart failure. Chapter Two is a report of an analysis of spirometry measures
made in patients with heart failure who were suspected to have comorbid COPD. This
secondary analysis explored the predictive power of forced vital capacity (FVC), forced
expiratory volume in one second (FEV1), and the ratio between the two (FEV1/FVC), for
event-free survival in these patients. Cox proportional hazard modeling was used to
examine the relationship between spirometry measures and all-cause
hospitalization/mortality with and without adjusting for demographic and clinical
covariates. Cox proportional hazards regression models compared all-cause
hospitalization/mortality between those with and without airflow limitation. Those with
airflow limitation were 2.2 times more likely to be hospitalized or die compared to those
without (HR: 2.20, 95% CI 1.06 – 4.53, p = .03) Those in New York Heart Association
functional class III/IV were 73% more likely to have an event (HR: 1.73, 95% CI 1.00 –
3.01, p = .05) when compared with those in NYHA class I/II. Patients who had never
smoked were 62% (HR: 0.38; 95% CI 0.17 - 0.81, p = .01) less likely to have a healthrelated hospitalization/death.
Often, when pulmonary function decreases (indicating disease progression), key
outcomes such as health related quality of life (HRQoL), functional capacity and
cognition may also decline. As the disease progresses, it is common for patients to have
caregivers, friends, family or significant others to help them manage their disease.

4

Chapter Three contains a psychometric evaluation of the Multidimensional Scale of
Perceived Social Support (MSPSS) in a sample of patients with comorbid COPD and
heart failure. The MSPSS measures perceived social support from friends, family, and
significant others. The MSPSS was evaluated for internal consistency with Cronbach’s α
and the split-half technique. Construct validity of the MSPSS was assessed with a factor
analysis and hypothesis testing. The MSPSS demonstrated excellent internal consistency
with Cronbach’s alpha consistently above .90. Factor analysis yielded a 3-factor solution,
with items loading appropriately on the Friend, Family and Significant Other subscales.
Hypothesis testing supported our hypothesis that higher levels of perceived social support
predicted higher self-care management score (F [11, 291] = 2.463, R2 = .051, B = .151, p
= 0.03). The MSPSS is a valid and reliable instrument to measure perceived social
support in patients with comorbid COPD and heart failure.
There is a lack of evidence about the immediate effects of self-care interventions
on key outcomes, particularly symptom burden (severity of distress due to cough, chest
tightness, distress due to mucous production, dyspnea with activity, dyspnea at rest,
fatigue, anxiety, and depressive symptoms). Chapter 4 reports a test of a theory-based,
multidimensional, self-care educational intervention using an eHealth platform, on
symptom severity and variability, anxiety and depressive symptoms, perceived self-care
ability, self-care adherence, and self-care information needs (knowledge) needs in
patients with COPD. Multilevel growth models were constructed to examine symptom
severity and variability. Repeated measures analysis of variance examined the effect of
the intervention on anxiety and depressive symptoms, and perceived self-care ability at
the end of week 1, 2 and the conclusion of the reporting period. Paired t-tests determined
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the effect of the intervention on perceived self-care adherence and self-care information
needs (knowledge).
Growth model analyses revealed that participants categorized as having medium
symptom severity at baseline perceived the following symptoms as more distressful
during the intervention period: distress due to cough (b = 10.16, 95% confidence interval
[CI] 1.95 – 18.40, t(83) = 2.46, p = .02), chest tightness (b = 8.47, t[103] = 2.06, p = .04),
dyspnea with activity (b = 13.18, t[82] = 1.97, p = .05), and fatigue (b = 16.48, t[134] =
3.89, p < .01). However, those categorized as high severity at baseline reported
significantly lower severity of chest tightness after the intervention (b = -8.15, t[113] = 2.03, p = .04). There were no demonstrated effects of the intervention on symptom
variability, anxiety, depressive symptoms or perceived self-care ability. However, there
were improvements in perceived self-care adherence (baseline - 58.1 + 19.3, post
intervention - 67.6 + 12.2, p = .025) and self-care information needs (knowledge) scores
(baseline - 13.7 + 3.1, post intervention - 11.3 + 1.8, p = .012) after implementation of the
intervention.
Chapter Five concludes the dissertation with an overall summary of findings from
the included manuscripts and the conclusions derived from these studies. Furthermore, in
this chapter, implications for practice, as well as future directions for research in this
population are proposed.

6

CHAPTER TWO
Airflow limitation more than doubles the risk for hospitalization/mortality in patients
with heart failure.

Synopsis
Comorbid chronic obstructive pulmonary disease (COPD) is found in
approximately one third of patients with heart failure (HF). Survival in patients with
COPD generally decreases as lung function declines. However, the association between
lung function, hospitalization and survival is less clear for patients with HF. This
manuscript reported a secondary data analysis about the predictive power of spirometry
measures for the combined variable, hospitalization/mortality, in patients with HF. This
analysis revealed that participants with airflow limitation were 2.2 times more likely to be
hospitalized or die compared to those without airflow limitation. Those in NYHA
functional class III/IV were 73% more likely to have an event when compared with those
in NYHA class I/II. Patients who had never smoked were 62% less likely to have a
health-related hospitalization/death. Thus, there is an increased need to screen and
appropriately manage patients with heart failure and airflow limitation to reduce the risk
for hospitalization/mortality.

7

Introduction
Chronic heart failure (HF) and chronic obstructive pulmonary disease (COPD) are
two of the top four causes of global mortality; HF and COPD account for approximately
21.5 million deaths/year worldwide.1,32 Up to one third of patients diagnosed with HF
also exhibit some degree of COPD, and approximately 40% of patients diagnosed with
COPD have heart disease.30,31 HF and COPD share a number of commonalities that
include the age of the affected population, cigarette smoking as a risk factor, presence of
systemic inflammation, periodic episodes of disease exacerbation that require
hospitalization, and dyspnea as a prominent symptom.29 Individuals diagnosed with
concomitant heart disease and COPD are two to five times more likely to die of heart
disease or stroke compared to those with heart disease alone.29,30 These two chronic
diseases are also associated with a number of other worse patient outcomes.
Prior investigators found that patients with comorbid COPD and HF reported
decreased health-related quality of life, higher prevalence of anxiety and depressive
symptoms, as well as the highest hospitalization rates among individuals with chronic
diseases.33-35 Specifically, patients with heart failure reported 2.5 times poorer health
related quality of life scores and 52% worse functional capacity scores, demonstrated 2.5
to 3 times worse depression and anxiety scores compared to healthy individuals, and
accounted for 25.6% of all hospitalizations.36,37 In patients with COPD, up to 99% of
patients reported symptoms that impaired activities of daily living, and 7% to 80%
reported feeling anxious and/or depressed.38,39 Patients with COPD were also 85% more
likely to be diagnosed with an anxiety disorder, and twice as likely to be hospitalized for
exacerbations when compared to healthy people. 13-16 In 2009, patients with COPD
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accounted for approximately 16% of all hospitalizations.37 Other investigators found the
combination of COPD and comorbid HF was associated with a 2.8 times greater
likelihood of worse quality of life, and a dyspnea burden 2 to nearly 3 times greater than
those with HF only.40,41 Thus, HF and COPD have a high symptom burden, poor
outcomes and require significant healthcare utilization.
Spirometry provides measures of inhaled and exhaled lung volumes, lung
capacity, and rates of gas flow.4 Spirometry results provide information about the ability
to ventilate, and can be used as a screening measure, diagnostic measure, or a means of
disease monitoring.42 Diagnostic pulmonary function tests are more comprehensive and
include measures of respiration like diffusion capacity, the degree to which oxygen is
transferred from inhaled gas to erythrocytes in pulmonary circulation. Spirometry is used
to evaluate pulmonary conditions but is not commonly used in patients with HF unless
they have a suspected concomitant pulmonary condition. For this study, we used
spirometry measures to evaluate pulmonary ventilation in patients with HF and suspected
airflow limitation; these measures included forced vital capacity (FVC; liters), forced
expiratory volume in one second (FEV1; liters at one second), and the ratio between the
two (FEV1/FVC).
FVC is the maximum volume of air that is forcibly exhaled after a full inspiration;
the residual volume remains in the lungs and when added to the FVC provides the total
lung capacity. FVC is measured in liters and like FEV1, is compared to a predicted value
based on sex, age, height and weight.4,43 FEV1 is the volume of air forcefully exhaled in
one second after a full inspiration; it provides an evaluation of airflow. When the FEV1 is
less than 80% of the predicted value, airflow limitation is present.4,43 The ratio of FEV1 to
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FVC, also known as the Tiffeneau-Pinelli index, is the proportion of vital capacity that an
individual can forcefully exhale in the first second, and may be used to differentiate
obstructive from restrictive disease and identify disease severity.4,43 An FEV1/FVC <
0.70 is the global standard cut point for airflow obstruction/COPD.4 In those individuals
with FEV1/FVC < .70 after bronchodilator administration, individuals are then classified
based on severity of airflow limitation (Table 1.).
Spirometry measures that revealed airflow limitation were associated with poorer
outcomes that included worse quality of life, more hospitalizations, and mortality in
patients with COPD.44-46 Spirometry indices predicted mortality in patients with COPD,
and those with reduced FEV1 and FVC, had 43% to 50% higher associated risks for
mortality compared to those with normal values.47 Despite the overlap in signs,
symptoms, and pathological presentations, spirometry is not regularly performed in
patients with HF; thus, the relationship between spirometry measures and combined
hospitalization/mortality in patients with HF and airflow limitation has not been
systematically studied.46,48,49 Therefore, the purpose of this study was to explore the
predictive power of spirometry measures on event-free survival in patients with HF and
suspected airflow limitation. The specific aims were to: 1) determine the proportion of
patients with HF who exhibited airflow limitation (FEV1 < 80%) and met the spirometry
criteria for COPD (FEV1/FVC < 70%); and 2) determine the independent predictive
power of FEV1, FVC, and FEV1/FVC on a combined endpoint of
hospitalization/mortality, while controlling for age, gender, ethnicity, smoking history,
body mass index, left ventricular ejection fraction, and New York Heart Association
(NYHA) functional class.
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Methods
Design and Sample
This was a secondary analysis of data from a registry of three prospective,
longitudinal studies conducted between 2008-2011.50-52 Each of the study protocols were
reviewed and approved by respective Institutional Review Boards. These studies
conformed to the principles outlined in the Declaration of Helsinki. Informed, written
consent was obtained from all participants after they were approached by a trained
research nurse who confirmed patient eligibility, explained the study requirements, and
all risks. Individuals were included if they had a primary diagnosis of HF, read/spoke
English, had no obvious signs of cognitive impairment, and were at least 18 years old.5052

Patients were recruited from a southern academic medical center in the United States.

For this analysis, we filtered the original data registry to obtain only those cases with
complete data for specific sociodemographic and clinical variables that might confound
our analyses, and for our variables of interest, spirometry measures (FVC, FEV1,
FEV1/FVC) and the outcome, time to combined hospitalization/mortality. There were 137
participants with complete data included in this secondary analysis.
Measures
Demographic and Clinical Variables
Sociodemographic and clinical data were collected by patient interview and
review of medical records. Demographic variables included age, gender, and ethnicity.
Clinical variables included smoking status, left ventricular ejection fraction (LVEF), New
York Heart Association (NYHA) functional class, and body mass index (BMI).
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Spirometry
Spirometry measures were obtained from enrolled patients to determine the
prevalence and degree of occult airflow limitation. All spirometry measures were made
by fully trained respiratory therapists according to the American Thoracic Society’s
guidelines for acceptability and reproducibility of lung function testing.43,53 GOLD
criteria4 were used to establish cut points for airflow limitation and COPD. Per GOLD
criteria, airflow limitation was defined as [actual FEV1/predicted FEV1 ] < 80%; this was
the cut point used to identify participants with airflow limitation for this analysis.4
Airflow obstruction (COPD) was defined as a FEV1/FVC < 70%; this is the cut point
used to identify patients with probable COPD for this analysis.4
Combined Hospitalization/Mortality
The outcome of interest in this study was time to the composite end-point of allcause combined hospitalization/mortality. Patients in this study were followed for up to
four years (maximum = 1454 days), and data about all hospitalizations and mortality
were collected. Every patient previously identified family member or specified friend was
contacted with monthly phone calls to evaluate health status. Events reported were
confirmed by review of medical records or death certificate. All events were confirmed
and classified by a trained cardiac nurse and heart failure expert.
Data Analysis
Patient characteristics were summarized using means, standard deviations or
frequencies. Participants were grouped based on the FEV1 % of predicted with 0.80 used
as the cut point, and were divided into those with airflow limitation or no airflow
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limitation.4 These groups were compared with an independent t-test, Chi-square, or
Fisher’s exact analysis based upon level of measurement and distribution of data. To
respond to Specific Aim 1, patients were grouped based on FEV1 value; individuals with
an FEV1 of < 80% of predicted were considered to have airflow limitation; those with an
FEV1 < 70% of predicted were categorized as COPD.
To address Specific Aim 2, we performed Cox proportional hazard modeling. The
relationship between spirometry values and the composite outcome of combined all-cause
hospitalization/mortality was tested with and without adjusting for age, gender, ethnicity,
smoking status, LVEF, and BMI. First, spirometry data (FEV1, FVC and FEV1/FVC)
were analyzed as continuous variables independently and with the control variables,
using Cox proportional hazards regression to examine the overall effect of spirometry on
combined all-cause hospitalization/mortality. Then, Cox proportional hazards regression
modeling was conducted using participant classification of those with airflow limitation
(FEV1 < 80%) and/or presence of COPD (FEV1/FVC < .70), with and without control
variables. All test assumptions were evaluated prior to analysis. All data analyses were
performed using SPSS version 24.0 (IBM, Armonk, NY), and a p value of < 0.05 was
considered significant.
Results
Characteristics of the participants
Participants in this study were primarily male (68%), Caucasians (79%) who were
60 + 12 years of age (Table 2.). Slightly more than half of participants were in NYHA
functional class I or II (52%), and on average the LVEF was 36 + 15%. Approximately
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42% of participants reported never smoking, while 18% reported they were current
smokers. Baseline spirometry measures averaged FVC of 2.98 + 0.90 L (74% of
predicted value), an FEV1 of 2.24 + 0.68 L/sec (69% predicted value), and FEV1/FVC of
0.75 + 0.08. Only 10% of participants had received a prior diagnosis of COPD. The
follow up period for the composite outcome of hospitalization/mortality ranged from 7
days to 1454 days. There were 199 hospitalizations during this period and 9 participants
died. Mean time to first event was 378 + 270 days.
Prevalence of airflow limitation
We first categorized patients based on FEV1 and FEV1/FVC (Table 3). Overall,
74% (n = 102) of participants exhibited some degree of airflow limitation (FEV1 < 80%
predicted value) and 26 (19%) participants met the spirometry criterion for COPD
(FEV1/FVC < 0.70). Only 14 participants were previously diagnosed with COPD; thus,
9% of total participants met spirometry criterion for COPD, but had not been diagnosed.
Association of spirometry measures as continuous variables with event-free survival
Cox proportional hazard regression demonstrated no significant effect of FVC,
FEV1, or FEV1/FVC on event free survival when treated as continuous variables, with
and without controlling for potential confounding demographic and clinical variables
(Table 4.) The overall Cox proportional hazard regression was insignificant; there was no
significant effect of spirometry measures independently or after controlling for potential
confounding variables on all-cause hospitalization/mortality. However, FEV1 was
significantly correlated with time (days) until first event (r = .22, p = .01), which
indicated that as FEV1 decreased (greater airflow limitation), time to event was shorter.
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Association of spirometry groups and event-free survival
In simple Cox regression modeling (Table 5.), airflow limitation (FEV1 < 80%)
independently predicted all-cause event-free survival (HR: 2.40, 95% CI 1.22 – 4.69, p =
.01). After controlling for age, gender, ethnicity, smoking status, LVEF, and BMI,
patients who demonstrated airflow limitation had 2.2 times the risk of
hospitalization/mortality (HR: 2.20, 95% CI 1.06 – 4.53, p = .03) when compared to
patients with no airflow limitation (Figure 1). Those in NYHA class III/IV were 73%
more likely to have an event (HR: 1.73, 95% CI 1.00 – 3.01, p = .05) when compared
with those in NYHA class I/II; conversely, if patients reported they had never smoked,
they were 62% (HR: 0.38; 95% CI 0.17 - 0.81, p = .01) less likely to have a health-related
hospitalization/death when compared to patients who currently had or ever had a smoking
habit.
Discussion
We found that a majority of participants with HF (73%) had some degree of
airflow limitation, and approximately 19% of participants met diagnostic criteria for
COPD based on spirometry; 9% (n = 12) of these patients were unaware their spirometry
measures were consistent with a diagnosis of COPD. Moreover, a FEV1 < 80% was
highly associated with our combined composite endpoint of hospitalization/mortality;
NYHA functional class III/IV was also associated with increased risk for
hospitalization/mortality. Never smoking was associated with a reduced risk for an event.
There was no association between FVC, FEV1/FVC (as continuous or categorical), age,
gender, ethnicity, LVEF, or BMI with event-free survival in this sample of patients with
HF.
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Other investigators have explored the prevalence of airflow limitation and COPD
in patients with HF; in prior research studies, 49% - 81% of patients with HF
demonstrated airflow limitation and 11% - 39% of patients met spirometry criterion for
COPD.46,48,49,54,55 In our sample of patients with HF, we found that the prevalence of
airflow limitation (74%) and COPD (19%) was similar. However, there was considerable
variability in the characteristics of the participants in prior studies, the procedures and
equipment used, and criteria used to identify airflow limitation. For example, Arnaudis
and colleagues48 studied patients with more advanced HF (higher proportion of patients
in NYHA III/IV) who were clinically unstable; while Bektas and colleagues54 studied
patients with less advanced disease (higher proportion of NYHA class I/II) who were
clinically stable. Bektas and colleagues54 also measured patient spirometry after
administration of a bronchodilator; while Plesner and colleagues46 measured spirometry
without bronchodilator. Wada and colleagues55 used a handheld spirometer and
diagnostic criteria based on FEV1/FEV6 to identify airflow limitation, rather than
conventional office-based measures and GOLD criteria.4 Plesner and colleagues 46 used
standardized, calibrated spirometry equipment and the European Respiratory Society’s
standards and guidelines; other investigators did not clearly describe the procedure and
equipment used.49 Thus, there is a clear need for investigators to use standardized,
calibrated equipment and procedures for spirometry measures, and criteria for airflow
limitation, so that reported results between studies will be comparable.
Few prior investigators explored the association of spirometry measures with allcause hospitalization or mortality in patients with HF.46,48,49 We analyzed the overall
effect of airflow limitation, rather than diagnosis of COPD in our analyses and found that
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patients with any degree of airflow limitation had more than twice the risk of
hospitalization/death. Similarly, Plesner and colleagues46 found that FEV1 was
independently associated (HR 1.43, 95% CI 1.21 – 1.68, p < .001) with all-cause
mortality after adjusting for similar potential confounding variables; however, Arnaudis
and colleagues48 reported FEV1 was significantly associated with all-cause mortality only
in the presence of verified COPD (GOLD stage II: HR: 2.28, 95% CI 1.218–4.25; p =
0.01; GOLD stage III/IV: HR: 2.81, 95% CI 1.03–7.69; p = 0.044). Other investigators
developed inconsistent conclusions about COPD (FEV1/FVC < 0.70) as a significant
prognostic indicator of event-free survival. Plesner and colleagues46 concluded that a
COPD diagnosis was not significantly associated with all-cause mortality after
controlling for demographic and clinical variables (HR: 1.26, 95% CI: 1.85-1.87, p =
.26);46 similarly, Mascarenhas and colleagues49 also concluded that a diagnosis of COPD
was not significantly associated with all-cause mortality after controlling for potential
confounding variables (HR: 1.40, 95% CI 0.88-2.24).49 Thus, our findings are consistent
with previous investigators and demonstrate that airflow limitation rather than COPD
diagnosis was associated with increased risk for all-cause hospitalization/mortality.
Overall, our participant characteristics were similar to those in previous
studies.46,48,49 However, our results must be weighed cautiously when compared to the
results of other studies. Our sample averaged a 12% lower proportion of patients in
NYHA class I/II than in our analyses; our participants were 4 years younger on average,
we had 6% fewer males on average, and had a 6% greater average LVEF compared to
those in other investigations.46,48,49 We also studied a different endpoint from other
investigators. We combined time to first hospitalization and mortality, rather than solely
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hospitalization or mortality.46,48,49 We studied this endpoint to determine the association
between airflow limitation and time to both events in this population. Thus, our findings
demonstrated a significant association between airflow limitation and
hospitalization/mortality in our patients with HF. This finding could aid in the
identification of patients likely to require hospitalization and may permit optimization of
both cardiac and pulmonary function and improvement in outcomes.
We also found that NYHA class III/IV and never smoking were significantly
associated with all-cause hospitalization/mortality. We found that worse functional class
was associated with 73% greater likelihood of an event (HR: 1.73, 95% CI 1.00 - 3.01, p
= .05). Several other investigators found that worse functional class was associated with 2
to 2.25 times greater likelihood of all-cause mortality.46,48,49 Our results are consistent
with previous investigators; thus, as functional class worsened, there was a consistently
increased risk for all-cause hospitalization/mortality. We also found that never smoking
was protective for our endpoint, all-cause hospitalization/mortality. Our participants who
had never smoked reduced their risk of hospitalization/mortality by 62% compared to
those who were current smokers or had previously smoked (HR: 0.38, 95% CI, 0.17 –
0.81, p < .01). Plesner and colleagues also found that current smokers had a 64% greater
risk of mortality compared to non-smokers (HR: 1.64, 95% CI 1.10 – 2.43, p = .014).46
Limitations
This study was a secondary data analysis; thus, we could include only the
variables measured in the primary studies. We also had no ability to appraise data for
accuracy or evaluate fidelity to study protocols. However, spirometry measures were
made in a pulmonary function laboratory using standardized equipment, procedures and
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highly trained personnel. Our spirometry data were measured without the use of
bronchodilation. Thus, our estimates of the prevalence may have included those with
some degree of reversible airflow limitation. All data were evaluated for accuracy by the
original investigative team and all data were double entered and evaluated for entry
accuracy prior to analysis.
Conclusions
A majority of our participants demonstrated some degree of airflow limitation.
Airflow limitation more than doubled the risk of all-cause hospitalization/mortality in our
patients with HF. Worse NYHA functional status was also associated with shorter
survival time; never smoking reduced the likelihood of hospitalization/mortality.
Spirometry measures may be useful in patients with HF, as tailored management of
airflow limitation may improve all-cause survival.
Implications for practice
•

Airflow limitation was common (74%) in this group of individuals with HF.

•

Airflow limitation increased risk of hospitalization/death by 220%.

•

Worse NYHA functional class was associated with 73% increased risk of shorter
survival time.

•

Non-smokers were 62% less likely to be hospitalized/die compared to smokers.

•

Patients with HF may be unaware they have airflow limitation or occult COPD;
approximately 10% of patients did not have a previous diagnosis of COPD but
met spirometry criteria for COPD.
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Table 2.1. Classification of airflow limitation severity based on FEV1 in patients with
FEV1/FVC < 0.70
GOLD Stage

Severity

FEV1

GOLD Stage 1

Mild

FEV1 > 80% predicted

GOLD Stage 2

Moderate

50% ≤ FEV1 ≤ 80%
predicted

GOLD Stage 3

30% ≤ FEV1 ≤ 50%

Severe

predicted
GOLD Stage 4

Very Severe

FEV1 < 30% predicted

Abbreviations: GOLD, Global Initiative for Obstructive Lung Disease; FEV1, Forced
Expiratory Volume in one second
Source: From the Global Strategy for the Diagnosis, Management and Prevention of
COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017.
Available from: http://goldcopd.org/.
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Table 2.2. Participant characteristics
Total sample

Airflow Limitation

No Airflow

P

N = 137

[FEV1 < 80%

Limitation

value

predicted]

[FEV1 ≥ 80%

n = 102 (74%)

predicted]
n = 35 (26%)

Age in years

60 + 12

59 + 11

63 + 13

.28

93 (68%)

70 (69%)

23 (66%)

.75

Caucasian

108 (79%)

75 (74%)

33 (94%)

.01

Other

29 (21%)

27 (26%)

2 (6%)

Current smoker

24 (18%)

21 (21%)

3 (9%)

Stopped smoking

56 (41%)

41 (40%)

15 (43%)

Never smoked

57 (42%)

40 (39%)

17 (49%)

BMI

32.7 + 7.7

33.4 + 7.7

30.7 + 7.2

.13

LVEF %

36 + 15

35 + 15

39 + 14

.15

COPD?

14 (10%)

14 (13%)

1 (3%)

.12

Spirometry:

26 (19%)

26 (26%)

0 (0)

-

I/II

71 (52%)

49 (48%)

22 (63%)

.13

III/IV

66 (48%)

53 (52%)

13 (37%)

Gender
Male
Ethnicity

Smoking History
.25

Prior Diagnosis of

FEV1/FVC < 0.70
NYHA Functional
Class

Values are mean + SD or f (%)
Comparisons were performed with independent t tests, Chi square or Fisher’s exact test
based on level of measurement and distribution of data.
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Table 2.2, Cont.
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital
capacity; NYHA, New York Heart Association Functional Class; LVEF, left
ventricular ejection fraction; BMI, body mass index
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Table 2.3. Baseline spirometry for participants
Spirometry Measure

Total sample

Airflow

Normal Airflow

(n = 137)

Limitation

(FEV1 ≥ 80%

(FEV1 < 80%

predicted value)

predicted value)

(n = 35)

(n = 102)
FVC measured in liters

2.98 + .90

Predicted FVC for the total sample

4.03 + .95

Percent predicted

74.8 + 18

FEV1 measured in liters

2.24 + .68

Predicted FEV1 for the total

3.23 + .78

2.81 + 0.87

3.34 + 0.87

2.06 + 0.64

2.66 + 0.65

73.64 + 9.05

80.03 + 5.01

sample
Percent Predicted

70.2 + 18

FEV1/FVC (%)

75.27 + 8.65

Predicted FEV1/FVC for total

80.64 + 2.20

sample
Values are mean + SD or f (%)
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital capacity
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Table 2.4. Cox Regression Modeling: Spirometry Measures as Continuous Variables
with and without Covariates on Combined All-Cause Hospitalization/Mortality
Exp (β)

95% CI

p value

FVC

.71

.19 – 2.56

.60

FEV1

1.35

.22 – 8.32

.75

FEV1/FVC

.98

.92 – 1.04

.46

Age

1.03

.99 - 1.05

.08

Male

.67

.34 - 1.36

.19

Caucasian

.64

.31 – 1.33

.23

Never smoked

.36

.16 – .79

.01

NYHA Class III/IV

1.85

1.06 - 3.22

.03

LVEF

1.01

.99 - 1.03

.33

BMI

1.02

.98 - 1.06

.20

FVC

.80

.19 – 3.30

.76

FEV1

1.49

.20 – 11.00

.69

FEV1/FVC

.98

.92 – 1.04

.49

Block 2b

Block 1 a

Variables in Model

Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital
capacity; NYHA, New York Heart Association Functional Class; LVEF, left
ventricular ejection fraction; BMI, body mass index;
Omnibus Tests of Model Coefficients: a X2 = 2.31, p = .51; b X2 = 18.83, p = .09
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Table 2.5. Cox Regression Modeling: Spirometry Measures using GOLD Cut points
with and without Covariates on Combined All-Cause Hospitalization/Mortality
Exp (β)

95% CI

p value

FEV1 < 80%

2.40

1.22 – 4.69

.01

FEV1/FVC < 0.70

.93

.50 – 1.74

.82

Age

1.02

.99 - 1.05

.07

Male

.74

.34 - 1.24

.19

Caucasian

.76

.36 – 1.61

.48

Never smoked

.38

.17 – .81

.01

NYHA Class III/IV

1.73

1.00 - 3.01

.05

LVEF

1.01

.99 - 1.03

.17

BMI

1.02

.98 - 1.05

.37

FEV1 < 80%

2.20

1.06 – 4.53

.03

FEV1/FVC < 0.70

.90

.44 – 1.83

.77

Block 2b

1a

Block

Variables in Model

Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital
capacity; NYHA, New York Heart Association Functional Class; LVEF, left
ventricular ejection fraction; BMI, body mass index;
Omnibus Tests of Model Coefficients: a X2 = 7.83, p = .03; b X2 = 22.03, p = .02
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Figure 2.1. Kaplan-Meier plots: spirometry and all-cause event-free survival (X2 =
22.03, p = .02)
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CHAPTER THREE
The Multidimensional Scale of Perceived Social Support in patients with Comorbid
COPD and Heart Failure: A psychometric analysis.

Synopsis
Chronic disease self-management is complex and multidimensional; individual
ability to perform self-management behaviors is influenced by comorbid conditions,
somatic awareness, and perceived social support. Optimal performance of complex selfmanagement behaviors requires individuals have the support of their friends, family
members, and significant others. This secondary data analysis reported the psychometric
properties of the Multidimensional Scale of Perceived Social Support (MSPSS) in
patients with comorbid chronic obstructive pulmonary disease (COPD) and heart failure
(HF). The MSPSS demonstrated excellent internal consistency with Cronbach’s alpha
consistently above .90. Factor analysis yielded a 3-factor solution, with items loading
appropriately on the Friend, Family and Significant Other subscales. Hypothesis testing
supported our hypothesis that higher levels of perceived social support predicted higher
self-care management score. We concluded the MSPSS is a reliable and valid instrument
to measure perceived social support in patients with comorbid COPD and HF.

27

Introduction
Chronic and obstructive pulmonary disease (COPD) and chronic heart failure
(HF) are responsible for over 21 million deaths annually, and are two of the top four
causes of global mortality.1,32 It is estimated that up to 52% of patients with HF have
comorbid COPD.56 Comorbid COPD and HF are associated with a higher incidence of
other cardiovascular diseases, such as atrial fibrillation/flutter and hypertension.57
Moreover, the risk of developing HF among patients with COPD is 450% greater
compared to healthy adults.58 COPD and HF are progressive and irreversible; patients
are taught about daily self-care behaviors to maintain functional ability, reduce symptom
burden, and maintain quality of life.13,19 Chronic disease self-care is complex and
multidimensional; individual ability to perform self-care behaviors is influenced by
comorbid conditions, somatic awareness, and perceived social support.13,59,60
Optimal performance of complex self-care behaviors requires individuals to have
the support of their friends, family members, and significant others. Perceived social
support plays an important role in outcomes such as self-care ability, depression, and
anxiety in patients with COPD. Previous investigators found that higher levels of
perceived social support was associated with higher self-care abilities (r = 0.252; P =
0.012), and was a significant predictor of reduced depression (β = -0.25, F(6, 85) = 5.10,
p <.01) and anxiety (β = -0.20, F(6, 85) = 5.61, p <.01).59,61,62 Furthermore, lower levels
of social support significantly predicted higher anxiety symptoms (F (11, 418) = 34.9, p <
.001, R2 adj = .47). Increased loneliness was moderately associated with worsening
depressive symptoms (r = −.587; p < .001) and reduced feelings of social support (r =
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−.471; p < .01).63,64 Thus, perceived social support is an important factor in patient
outcomes in those with COPD.
In patients with HF, perceived social support has been shown to predict level of
self-care ability (β = .33; p = .0002),65 and in a seminal study conducted by Riegel and
Carlson,66 patients who underwent an intervention to improve peer and social support
demonstrated a 8.7% increase in perceived self-care management ability (r = 0.46;
moderate effect), and a 6% increase in self-care confidence (r = 0.62; moderate/large
effect).66 In contrast, poorer social support was an independent predictor of reduced
health-related quality of life (β = −.132; P < .001), worse depressive symptoms (sβ =
−.467; P < .001) and was associated with a 50% increased risk of hospitalization and
death.67,68 Thus, there is an apparent association between social support and key
outcomes in patients with HF.
It is unclear whether patients with comorbid chronic conditions like COPD and
HF may require more perceived social support compared with individuals who have a
single chronic condition. It is plausible that the additive self-care requirements from each
disease would warrant greater perceived social support. It is vital that the instruments
used to measure perceived social support have psychometric rigor in patients with
comorbid conditions, so that the data obtained are reliable, valid and useful. Thus, the
purpose of this secondary analysis was to examine the psychometric properties of the
Multidimensional Scale of Perceived Social Support in patients with comorbid COPD
and HF. The specific aims of this study were to provide evidence of internal consistency
reliability and construct validity by factor structure and hypothesis testing. We
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hypothesized that higher perceived social support scores would predict better self-care
management.
Methods
Design and Sample
This study was a secondary data analysis from a large, multicenter HF registry.
This registry contains data from 4,076 inpatient and outpatient participants who were
recruited from cardiology centers located in the Southern and Midwest United
States.51,56,67-72 Recruitment and inclusion criteria were consistent across studies; study
participants had a confirmed diagnosis of HF with either preserved or reduced ejection
fraction, had a left ventricular ejection fraction (LVEF) < 40%, were 18 years or older,
and had not had a myocardial infarction within three months of enrollment. The selected
participants (N = 303) had complete data for demographic (gender, age, ethnicity, marital
status, years of education, smoking history) and clinical variables (diagnosis of HF,
diagnosis of COPD, LVEF, body mass index [BMI], New York Heart Association
[NYHA] functional class), and scores on the Multidimensional Scale of Perceived Social
Support (MSPSS), and self-management scores from the Self-Care for Heart Failure
Index (SCHFI).
Measures
Demographic and clinical variables were collected by interview of patients and
review of medical records. Demographic variables collected included gender, age,
ethnicity, marital status, years of education and smoking history. Clinical variables
include current diagnosis of COPD and HF, LVEF, BMI and NYHA functional class.
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Perceived Social Support
There is no consensus definition of perceived social support. However, perceived
social support is generally considered to be the physical, cognitive and psychological
benefits of interacting with other people.73 Zimet and colleagues74 developed the
Multidimensional Scale of Perceived Social Support (MSPSS) to measure perceived
availability and sufficiency of support from family, friends and significant others.74 The
MSPSS is a self-report instrument with 12 items that are rated on a 7-point Likert scale,
ranging from 1 “strongly disagree” to 7, “strongly agree”; this instrument has 3 subscales;
family, friends, and significant other. “Significant other” is intentionally undefined so
that the respondent can identify their own significant other(s).74,75 The MSPSS is scored
by summing the responses of the 12 items; total scores range from 12 to 84, and higher
scores indicate higher levels of perceived social support. The three subscales are also
scored individually and may be used independently in analyses.74,75
Internal consistency for this instrument in patients with HF previously ranged
from 0.85 to 0.94.68,76 During the initial instrument development, internal consistency for
the subscales ranged from .85 to .91, and test-retest reliability ranged from .72 to .85;74,75
internal consistency for the family, friends and significant other subscales in patients with
HF were .94, .94, and .94 respectively.77 Adequate construct validity was demonstrated
by repeated extraction of three factors in patients with HF77 as well as other populations
including undergraduate students, pediatric residents, European adolescents, pregnant
women and patients with end stage renal disease.74,75,77,78
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Self-Care Management
Self-care management is the process by which individuals with chronic disease
attain optimal health through learned, intentional actions that include symptom
recognition and response, adherence to prescribed treatment and medications, intentional
lifestyle alterations, regular interaction with health care professionals, and evaluation of
these actions.13 Self-care management was measured with the Self-Care Management
subscale of the Self-Care of Heart Failure Index (SCHFI).79 The SCHFI comprises three
subscales labeled self-care maintenance, self-care management, and self-care confidence;
each scale is measured and evaluated independently.79 Only the self-care management
subscale was used for our analyses because it assesses symptomatic patients and their
ability to perform management level behaviors, which are theoretically indicative of selfcare mastery.80 This subscale contains six items that measure symptom recognition,
implementation of treatment strategies, and evaluation of treatment strategies. This
subscale uses a 4-point Likert scale where 1 signals rarely or never, 2 signals sometimes,
3 indicates frequently, and 4 indicates always or daily. The six item scores are summed,
then transformed to produce a standardized range of potential self-care management
scores from 0 to 100; higher scores indicate better self-care management ability.79 A
score of 70 or greater indicates adequate self-care management.79 Cronbach’s alpha for
this subscale is acceptable and ranges from .597 to .70.79,80 Evidence of construct validity
for the SCHFI and self-care management subscale is strong, with consistent extraction of
three independent factors (for each of the three subscales) and consistent loading of the
appropriate questions on the self-care management construct.79,80
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Procedure
The participants included in this secondary data analysis were recruited after each
study was approved by the respective Institutional Review Board. All participants
provided informed consent. Data were collected by nurse researchers who were trained to
perform the study procedures. Nurse researchers were present during the data collection
process to aid participants as needed. All data were double entered into a data spreadsheet
(SPSS version 21, Armonk, NY) and evaluated for errors prior to analyses. We filtered
the data registry to obtain those participants with complete data for the demographic,
clinical and research variables of interest.
Data Analysis
Descriptive statistics, frequencies, means with standard deviations, and
proportions were used to characterize the participants. To analyze the internal consistency
of the MSPSS, Cronbach’s alpha was calculated for the total instrument and three
subscales. Item-item correlations were analyzed to ensure all correlation coefficients
were above 0.3 and below 0.9. Split-half reliability analyses were also conducted for the
total scale. A principal components factor analysis with a direct oblimin rotation was
conducted to examine the factor structure of the 12-item MSPSS. Sampling adequacy
was confirmed by a Kaiser-Meyer-Olkin measure above 0.5.81 Bartlett’s test of sphericity
was conducted to assess if correlations between items were sufficiently large to conduct
the analysis; a significant level of < .05 was used as the cut point for this analysis.81 To
further examine the construct validity of the MSPSS, hypothesis testing was performed
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using multiple linear regression. We hypothesized that higher perceived social support
score was a predictor of better self-care management score after controlling for age,
gender, ethnicity, marital status, living situation, smoking status, education level, BMI,
LVEF, and NYHA class. All data analyses were conducted using SPSS Version 24.0
(IBM, Armonk, NY). An a priori α level of < 0.05 was used to determine significance.
Results
Characteristics of the participants
Participants with comorbid COPD and HF (N = 303) were primarily male (63%),
Caucasians (65%) aged 61 + 12 years on average (Table 1.) A majority of these
participants were married or cohabiting (60%) and 74% reported living with someone.
Approximately two thirds (62%) of participants were classified as NYHA class III/IV
with an average LVEF of 37 + 15%. A majority of participants had a prior smoking habit
but had quit (43%), and 19% were current smokers. The average participant had 12.4 +
3.6 years of education. Total perceived social support scores were moderately high with
an average score of 63.5 + 17.3 Average self-care management scores (55 + 20) were
below the recommended cutoff of 70, indicating poor self-management scores in these
participants.
Internal Consistency Reliability
The MSPSS demonstrated excellent internal consistency yielding a Cronbach α =
0.93 for the total instrument, 0.95 for the Friend subscale, 0.92 for the Family subscale,
and 0.92 for the Significant Other subscale. Analysis of item-item correlations ranged
from .347 - .884. Cronbach’s α did not increase during removal of each item during
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reliability assessment. Split-half reliability analyses of the MSPSS resulted in a
Spearman-Brown coefficient of .92; a Spearman-Brown coefficient above .80 indicates
adequate correlation between split halves, and a good indicator of internal consistency of
the MSPSS in this sample.81
Construct Validity
A principal components analysis was conducted on the 12 items of the MSPSS
with a direct-oblimin rotation for this sample of patients with comorbid COPD and HF
(Table 2.). A preliminary analysis was conducted to ensure the data were appropriate for
further analysis by evaluation of the Kaiser-Meyer-Olkin statistic and Bartlett’s test of
sphericity. The Kaiser-Meyer-Olkin measure ensured sampling adequacy for this analysis
with a KMO = .880, which is well above the recommended cutoff of ≥ 0.60.81 Bartlett’s
test of sphericity (X2 (66) = 3393.17, p < .001) indicated that the correlations between
items were sufficiently large to conduct the analysis.81 An initial analysis was conducted
to obtain eigenvalues for each factor. Three factors had eigenvalues greater than Kaiser’s
criterion of 1 and accounted for 82.4% of the total variance; factor one had an eigenvalue
of 6.89, accounting for 57.4% of the total variance, and the other two factors combined
for 14.7% (eigenvalue 1.77) and 10.2% (eigenvalue 1.23) of the total variance.82,83 The
scree plot clearly supported a three-factor solution evidenced by a modest drop off after
the third factor. Thus, three factors were retained for the final analysis. A factor cut-off
was set at 0.40, with loadings below .40 eliminated from the final model.84 As a result,
there were no cross loadings of items between the three factors. Items that clustered on
the same factor suggested that component 1 represented the Family subscale, component
2 represented the Friends subscale and component 3 the Significant Other subscale. The
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extraction of three factors with no cross loadings replicated the original instrument
development and provided support for the three-factor structure in those with comorbid
COPD and HF.74,75
Multiple linear regression was used to evaluate construct validity of the MSPSS
(Table 3.). We hypothesized that higher perceived social support score would be an
independent predictor of better self-care management score after controlling for age,
ethnicity, marital status, living alone, education level, smoking history, BMI and NYHA
functional class. All variables were entered into the regression model in one block. The
assumptions of linearity, independence of errors, homoscedasticity, outliers, and
normality of residuals were evaluated and met before interpretation of results. In this
model, perceived social support score significantly predicted self-care management score
(F[11, 291] = 2.463, p < .01, R2 = .085, adj R2 = .051). Specifically, higher LVEF (B = .234, p < .01) and better perceived social support score (B = .151, p = 0.03) were
significant predictors of self-care management scores. Higher perceived social support
was predictive of higher self-care management score; for every 1 unit increase in the
MSPSS score, there was an associated 0.151 unit increase in self-care management score.
For every 1% increase in LVEF, there was a 0.234 decrease in self-care management
score. No other covariates were significant predictors of self-care management.
Discussion
We provided evidence that the MSPSS is a valid and reliable instrument when
used to measure perceived social support in patients with comorbid COPD and HF. Our
results supported the MSPSS as a highly reliable instrument with Cronbach’s α
consistently above .90 in these participants. Results from our factor analysis using
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principal components yielded a 3-factor structure consistent with the factor structure
elicited during the original scale development and with previous investigators.74,75,77 We
also conducted hypothesis testing to further test the construct validity of the MSPSS. We
found that perceived social support score and LVEF significantly predicted self-care
management score, which further supported the construct validity of the MSPSS in this
population.
Our results demonstrated excellent internal consistency. However, Cronbach’s α
surpassed the recommended threshold of .90, indicating potential redundancy within the
scale. Several items examined in the item-item correlation matrix had coefficients near
.90; the correlation coefficient between item 6 (My friends really try to help me) and 7 (I
can count on my friends when things go wrong) was .868; the correlation coefficient
between item 9 (I have friends with whom I can share my joys and sorrows) and 12 (I can
talk about my problems with my friends) was .884. High item-item correlations suggested
redundant examination of perceived social support from friends. To further test for
redundancy, the examination of Cronbach’s α with deletion of items from the scale was
conducted; Cronbach’s α did not decrease below .90 when items were deleted, indicating
redundancy was unlikely. Thus, our findings support strong reliability of the MSPSS in
patients with COPD and HF.
A factor analysis using principal components with a direct oblimin (oblique)
rotation yielded a 3-factor structure with items loading on each of the friend, family and
significant other subscales. These results are consistent with previous factorial validity
testing of the MSPSS; in patients with HF,77 pregnant women,75 adolescents,75,78 and
undergraduate students.74 A three-factor structure was produced with items corresponding
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to the dimensions of friends, family and significant other. The findings of our analysis are
consistent with previous investigator’s findings and support a three-dimension solution in
patients with concomitant COPD and HF.
Previous investigators have supported the importance of perceived social support
in performing self-care in COPD and HF populations separately; however, to our
knowledge, investigators have not tested the association of perceived social support with
self-care scores in patients with comorbid COPD and HF. Our results confirmed findings
from previous investigators who found that higher levels of perceived social support were
associated with better self-care management score.59,62,65,66 Thus, social support is an
important factor to consider when measuring self-care management for those with
comorbid conditions such as COPD and HF.
Additionally, we also observed that LVEF was a predictor of self-care
management score. For every 1% increase in LVEF, there was a 0.234 decrease in selfcare management score. This finding is consistent with previous investigators who
studied self-care management in patients with HF alone. Lee and colleagues 85 found that
worse functional class (NYHA III/IV) and higher ejection fraction were significant
predictors of poorer consulting behaviors; consulting behaviors were defined as actions
taken by patients to seek guidance about worsening symptoms.85 Patients with poor
consulting behaviors scored an average 12.3 points lower on the self-care management
subscale of the SCHFI compared to those patients who had good consulting behaviors.85
Patients who did not have highly burdensome symptoms or greater functional impairment
may have not needed to engage in self-care management behaviors;85,86 the self-care
management subscale is most relevant to symptomatic patients.80 Thus, patients with a
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higher LVEF likely had a lower symptom burden, which required less self-care
management; subsequently, these patients may not have fully developed self-care skills.
Limitations
The participants included in this secondary data analysis were derived from a
registry of patients with HF; thus, we had no control over the variables measured or the
data collection process and could not appraise the data for accuracy or validity. The
MSPSS and the SCHFI are self-report instruments and may be subject to social
desirability bias. However, all data collection procedures were designed to reduce the
potential for bias, and data input was evaluated by the original investigators for accuracy
prior to analysis.
Conclusion
The MSPSS was demonstrated to be a reliable and valid measure of perceived
social support from friends, family and significant others in patients with COPD and HF.
Further studies are warranted to determine the psychometric properties of the MSPSS in
patients with solely COPD, as well as to examine the relationship between comorbidities,
perceived social support and self-care.
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Table 3.1. Sample Characteristics (N = 303)
Variable

f (%) or mean + SD

Age in years

61 + 12

Gender
Male

192 (63)

Ethnicity
Other

105 (35)

Caucasian

198 (65)

Marital Status
Single/Widowed

64 (20)

Married/cohabitate

181 (60)

Divorced/Separated

58 (19)

Live with someone
Yes
Education in years

225 (74)
12.4 + 3.6

Smoking History
Current smoker

25 (34.7)

Non-smoker

47 (65.3)

BMI

31.5 + 7.9

LVEF

37 + 15

NYHA class
I/II

116 (38)

III/IV

187 (62)

Perceived Social Support (MSPSS)
Total score

64 + 17

Friend subscale

19 + 8

Family subscale

22 + 7

Significant Other subscale

23 + 7

Self-care management

55 + 20

(SCHFI subscale)
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Table 3.1, Cont.
Abbreviations: BMI, body mass index [kg/m2], LVEF, left
ventricular ejection fraction, NYHA, New York Heart
Association functional class
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Table 3.2. Rotated Pattern Matrix of the Multidimensional Scale of Perceived Social
Support in patients with COPD and HF (N = 303)
Item

Rotated Factor Loadings

Friend Support

Factor
1

2

3

6. My friends really try to help me.

.037

-.895

-.013

7. I can count on my friends when things go

.014

-.936

.016

-.012

-.914

-.035

.024

-.931

.003

3. My family really tries to help me.

.929

-.019

.070

4. I get the emotional help and support I

.895

-.004

-.052

.773

-.086

-.081

.903

.027

-.004

.116

.140

-.867

-.100

-.088

-.913

-.030

-.116

-.877

.071

.002

-.834

Initial Eigenvalues

6.890

1.767

1.227

Rotated Eigenvalues (direct oblimin)

5.143

5.115

5.274

wrong.
9. I have friends with whom I can share my
joys and sorrows.
12. I can talk about my problems with my

Family Support

friends.

need from my family.
8. I can talk about my problems with my
family.
11. My family is willing to help me make
decisions.

Significant Other Support

1. There is a special person who is around
when I am in need.
2. There is a special person with whom I can
share my joys and sorrows.
5. I have a special person who is a real
source of comfort to me.
10. There is a special person in my life who
cares about my feelings.
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Table 3.3. Multiple Linear Regression Variables Predicting Self-Care Management
Score (N = 303)
Model

Unstandardized Standard

Standardized

Variable

Coefficient

coefficient

error of the

P value

coefficient
Age

.112

.107

.065

.30

Gender

3.546

2.711

.084

.19

Ethnicity

.010

2.416

.000

.99

Marital Status

.937

1.394

.043

.50

Living

-.189

2.825

-.004

.95

.141

.350

.025

.69

1.778

1.163

.096

.13

BMI

.153

.163

.059

.35

LVEF

-.319

.084

-.234

< .01

NYHA Class

1.175

1.644

.044

.48

Perceived

.151

.070

.128

.03

Situation
Education
Level
Smoking
History

Social
Support
(MSPSS total
score)
Abbreviations: NYHA, New York Heart Association Functional Class; LVEF, left
ventricular ejection fraction; BMI, body mass index; MSPSS, Multidimensional
Scale of Perceived Social Support
R2 = .085, adjusted R2 = .051, df = 11, model F statistic = 2.463, p = .006
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CHAPTER FOUR
Effect of an eHealth Self-Care Educational Intervention on Symptom Severity and
Variability, Psychological Distress, Self-Care Ability, and Treatment Adherence and
Knowledge in Patients with COPD.
Synopsis
Patients with chronic obstructive pulmonary disease (COPD) experience a variety
of burdensome symptoms and are at higher risk of developing psychological symptoms
like anxiety and depressive symptoms compared with healthy individuals. Due to the
high symptom burden and progressive nature of COPD, healthcare providers prepare
patients with COPD to perform considerable self-care at home. This manuscript reported
a study about the effect of a theory-based, self-care education program on symptom
severity and variability, anxiety and depressive symptoms, perceived self-care ability,
self-care adherence, and perceived knowledge needs in patients with COPD. This
intervention resulted in significant change in symptom severity evaluation in subsets of
patients. Perceived self-care ability was unchanged; however, perceived self-care
adherence scores improved, and knowledge needs were significantly reduced after the
intervention.
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Introduction
Chronic obstructive pulmonary disease (COPD) is predicted to be the third
leading cause of death worldwide by 2030.1 In the United States, the estimated
prevalence of COPD ranged from 15 to 22 million (7-9% of the U.S population).2,3 Up to
99% of patients with COPD reported daily symptoms like dyspnea and fatigue, and 7% to
80% of patients with COPD described feeling anxious and/or depressed. COPD patients
are 85% more likely to be diagnosed with an anxiety disorder compared to healthy
controls, and twice as likely to be hospitalized for acute exacerbations.23,38,87 Due to the
high symptom burden and progressive nature of COPD, healthcare providers prepare
patients with COPD to perform considerable self-care at home. However, Nici and
colleagues24 suggested that approximately 60% of patients with COPD do not
demonstrate prolonged retention of self-care behaviors.
In the middle range theory of self-care of chronic illness, self-care is defined as
the process by which individuals with chronic disease attain optimal health through
learned, intentional actions that include symptom recognition and response, adherence to
prescribed treatment and medications, intentional lifestyle alterations, regular interaction
with health care professionals, and evaluation of these actions.16 The increased incidence
and prevalence of COPD has been the impetus for the development of education and
training programs focused on self-care behaviors for these patients. These structured,
multi-faceted interventions aimed to educate, motivate, engage, and support patients to
adapt their health behaviors and develop skills to prevent exacerbations requiring
hospitalization, and to provide relief of symptoms. 4,14-17
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There is a plethora of evidence to support an association between self-care
interventions and decreased dyspnea burden in this population; patients receiving selfcare interventions exhibit a 4.1%, to 16.6% decrease in dyspnea post-intervention
compared to controls.88-90 However, researchers have yet to demonstrate whether selfcare interventions have a significant effect on other highly burdensome symptoms such as
distress due to cough, chest tightness, distress due to mucous production, or fatigue.
Previous investigators have concluded that patients with COPD experienced an
assortment of symptoms with varying levels of intensity and variability throughout the
day, and from day to day; during any given day, 45.4% of people experience dyspnea,
60.1% had troublesome cough, 70.9% reported distress from mucous, 45.4% had chest
tightness, and 43.3% reported wheezing.5,91 Longitudinal symptom data in this population
are lacking. Prior investigators predominately assessed symptom severity and variability
using a cross-sectional approach, which failed to adequately capture daily symptom
profiles over time.5,6,91 Consequently, researchers have been unable to examine the
relationship between longitudinal trends in symptom variability and self-care strategies
aimed to reduce symptom burden.
Patients with COPD also experienced symptoms related to their mental health.
Approximately 7-80% of patients with COPD described daily anxiety with up to 40%
reporting symptoms consistent with clinical anxiety and 25% with clinically significant
depressive symptoms.12,23,92 Previous investigators concluded that self-care interventions
had no effect on anxiety and depression scores compared to those of a control
group.88,89,93-95 However, poor or ineffective management of anxiety or depressive
symptoms was independently associated with a 1.89 and 2.98 increased risk of
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hospitalization, respectively.28 These investigators concluded that anxiety and depressive
symptoms were important outcomes for patients with COPD, and future research is
warranted to explore the relationships between self-care and mental health outcomes.
To date, studies of self-care interventions have been primarily longitudinal with
periodic measures of outcomes collected monthly over the course of 3 to 12
months.88Studies of symptom severity and variability have primarily been cross-sectional
and have not examined symptom patterns in patients with COPD. Prior investigators have
not tested the effect of a self-care intervention on disease-related symptoms in the period
immediately following an intervention. Thus, it is unclear how quickly improvement
occurs after an intervention.
Previous self-care interventions have improved health related quality of life by
4.87% – 6.5%,15,18 reduced dyspnea scores by an average 16.6%,88 decreased risk for allcause hospitalization by 40%,20,21,88 reduced anxiety by an average 2.7%, and reduced
depression by an average of 2.9%.22,23 However, evidence is lacking about the immediate
effects of self-care interventions on perceived symptom severity and variability (distress
due to cough, chest tightness, distress due to mucous, dyspnea, or fatigue), perceived selfcare ability, self-care adherence, and self-care knowledge. We also lack data about the
use of electronic strategies for intervention delivery in this patient population. Thus, the
purpose of this study was to test the effect of a theory-based, self-care education program
using an eHealth platform on measures of symptom severity and variability (distress due
to cough, chest tightness, distress due to mucous, dyspnea with activity, dyspnea at rest,
fatigue, anxiety, and depressive symptoms), perceived self-care ability, self-care
adherence, and self-care information needs (knowledge) in a sample of adult patients
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with stable COPD. We hypothesized that participants would report lower levels of
symptom severity and variability, reduced anxiety and depression scores, better perceived
self-care ability and perceived self-care adherence, and fewer self-care information needs
during the intervention period (Days 8 – 21) compared to the pre-intervention period
(Day 1 – 7).
The aim of this study was to evaluate the effect of a 14-day, theory-based,
eHealth, self-care educational intervention on symptom severity and variability scores
(distress due to cough, chest tightness, distress due to mucous production, dyspnea with
activity, dyspnea at rest, fatigue, anxiety, and depressive symptoms), perceived self-care
ability scores, perceived self-care adherence scores (nutrition, physical activity, mental
health, breathing control, medical management, environment modification, and
exacerbation planning), and self-care information needs (knowledge scores) with baseline
measures in a group of stable patients with COPD (N = 20).
METHODS
Design
A quasi-experimental, simple, unbalanced, interrupted time series design (21
days) was used to determine the effect of an eHealth self-care educational intervention. A
simple unbalanced design was chosen so that participants served as their own control
(Days 1 – 7 no intervention, Days 8-21 intervention). Efficacy of the eHealth intervention
was determined by comparing data from the pre-intervention phase (Days 1-7) to data
from the intervention period (Days 8-21). Measures of symptom severity and variability,
perceived self-care adherence, self-care ability, and perceived COPD-specific knowledge
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needs were collected in a group of stable patients with COPD. Symptom data were
measured daily to evaluate symptom severity and variability. Measures of anxiety,
depression, and perceived self-care ability were measured at baseline, Day 8, Day 15 and
Day 21. Perceived self-care adherence and self-care information needs were measured at
baseline and on Day 21.
Sample
Patients age 40 to 70 years of age who were in the clinic for a routine follow up
visit with a primary or secondary diagnosis of COPD at a reigonal, community hospitalaffiliated pulmonary clinic in the southern United States, were screened for eligibility.
Patients were candidates for inclusion if they: 1) had a confirmed diagnosis of COPD
verified by pulmonary function tests demonstrating moderate to severe disease according
to GOLD criteria4 (forced expiratory volume in one second [FEV1]/ forced vital capacity
[FVC] <70% and FEV1 < 80%); 2) had stable disease state defined by absence of an
exacerbation in last three months; 3) had access to home Wi-Fi internet; 4) could read,
write and speak English; and 5) had a cell-phone with text messaging capabilities.
Patients were excluded if they had: 1) presence of symptomatic cardiovascular diseases
or severe systemic diseases (end-stage liver or renal disease, systemic lupus
erythematosus or malignancy); 2) impaired eyesight prohibiting accurate visualization of
tablet font as evidenced by failure to correctly read the tablet home screen application
list; 3) cognitive impairment as demonstrated by a score of < 2 on the Mini-Cog; or 4)
low health literacy as evidenced by a score of more than four incorrect responses on the
Newest Vital Sign instrument.
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A required sample size of 18 patients with at least 8 complete time points was
determined by an a priori power analysis estimate. This estimate was based on a one-way
repeated measures analysis of variance (ANOVA) power estimation with GreenhouseGeisser approximation, obtained using nQuery Advisor,96 which assumed there were 8
time-periods; 8 was the maximum number allowed by the software. With approximately
18 participants completing the trial, an alpha level of .05, and assuming that successive
observations from the same participant had a modest correlation of at least 0.3, the power
of the repeated measures F test to detect a medium effect size should exceed 69% to
detect changes in outcomes in the time period pre-intervention to the intervention period.
Two additional participants were added in case of attrition for a final sample size of 20
participants.
Measures
Clinical and sociodemographic variables
Sociodemographic variables included age, sex, ethnicity, highest education level,
marital status, employment status, and living situation. Clinical data included height,
weight, body mass index (BMI), spirometry measures (forced expiratory volume/second
[FEV1], forced vital capacity [FVC], FEV1/FVC, reference FEV1, reference FVC and
reference FEV1/FVC), GOLD stage (indicator of severity of disease), number of
exacerbations in past year, smoking status (packs per day and pack years), and current
prescribed medications. These data were obtained from medical record review and
interview.
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Symptom severity and variability
Symptom severity and variability were defined as the individual evaluation of the
degree of intensity and self-perceived change in disease-related symptoms over the
course of 24 hours for symptoms that included distress due to cough, chest tightness,
distress due to mucous, dyspnea with activity, dyspnea at rest, and fatigue. A modified
version of the Daily Symptom Scale (DSS)97 was used to measure symptom severity and
variability. The 6-item, modified DDS (symptom diary) prompted the participants to rate
the severity of their symptoms daily. Symptoms were rated on a 100-point visual analog
scale (VAS) where 0 was absence of a symptom and 100 was the most distressful the
symptom could be.97 The DDS has been shown to be reliable in patients with similar
chronic conditions such as cardiovascular disease and heart failure.97 Face validity of the
modified DDS was confirmed by two pulmonary care experts. Reliability of a
computerized visual analog scale has been shown to be low to moderate with test-retest
reliability coefficient of 0.44 – 0.56 and strong convergent validity was demonstrated
with non-computerized measures.98
Anxiety and depressive symptoms
Anxiety is a feeling of worry, nervousness, or unease, typically about an
imminent event or something with an uncertain outcome.99-101 Depressive symptoms can
be characterized by feelings of sadness, loss of interest and potential suicidality.102 The
Hospital Anxiety and Depression Scale (HADS) was used to measure anxiety and
depression.103 The HADS is a 14-item self-report questionnaire with a 7-item anxiety
subscale and 7-item depression subscale. The anxiety subscale (HADS-A) reflects a state
of generalized anxiety and the depression subscale (HADS-D) primarily focuses on the
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concept of anhedonia commonly experienced in depression. Each question is rated on a
4-point Likert scale ranging from 0 - absence to 3 - extreme presence. Each subscale can
be used independently, and scores range from 0-21 for each subscale; a total score out of
42 is calculated, with higher scores indicating greater levels of anxiety, depression and
overall psychological distress.103,104 Subscale scores of eight or higher indicate probable
anxiety and/or depressive symptoms; the HADS has well established validity, reliability
and diagnostic accuracy for measurement of anxiety and depressive symptoms in patients
with COPD.103,105-108
Self-care ability
Self-care ability was defined as, “the core behavioral and cognitive abilities which
presumably contribute to sustainable well-being”.109 Self-care ability was measured with
the Self-Management Ability Scale-Short (SMAS – S),109 a shortened version of the
SMAS-30.110 It is an 18-item questionnaire that has been used in patients with
COPD111,112 and other chronic illnesses.111 The SMAS-S total score assesses selfmanagement ability with items in six sub-scales that include taking initiative, investment
behavior, variety, multi-functionality, self-efficacy and positive frame of mind.18,110,113
The taking initiative, investment behavior, and positive frame of mind subscales are
scored on a 6-point Likert scale, with responses ranging from “never” to “very often”.
The variety subscale is scored on a 6-point Likert scale with responses ranging from
“none” to “more than six”. The multi-functionality subscale is scored on a 5-point Likert
scale with responses ranging from “strongly disagree” to “strongly agree”. The selfefficacy subscale uses a 5-point Likert scale with responses ranging from “I’m certain
that I cannot” to “I’m certain I can”. Each sub-scale can be used independently, or all 18
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questions can be used as a total composite score for self-care ability. The higher the
score, the better the perceived self-care ability; total scores can range from 18 to 102, and
there is no established cutoff for this scale.109 The six sub-scales had satisfactory internal
consistency with Cronbach’s α ranging from 0.69 to 0.77. Construct validity was
determined using confirmatory factory analysis and hypothesis testing, which yielded
unidimensionality among each of the subscales, underlying factors measured the
theoretical constructs of self-care ability, and moderate to high correlation with other
established measures of self-care and well-being in patients with COPD and other similar
chronic illnesses.109,111
Self-care adherence
Self-care adherence was defined as the extent to which an individual follows the
self-care recommendation/prescription.114 Self-care adherence was measured with a
modified version of the Medical Outcome Study Specific Adherence Scale (MOSSAS).114 The modified MOS-SAS is an eight-item instrument that assesses adherence for
each of the seven self-care domains included in this study. These included nutrition and
diet, physical activity, mental health, breathing control, medical management,
environment modification, and exacerbation planning. The MOS-SAS evaluates, “How
often have you done each of the following in the past week?” and each answer is
measured on a 6-point Likert scale ranging from 0-none of the time, to 5-All of the time.
Each response is weighted to achieve a range of possible total score of 0–100; all items
are added then averaged and there are no established cut points for this scale.115 Internal
consistency for the MOS-SAS ranged from 0.50 to 0.78 in similar chronic disease
populations who require sustained, lifelong treatment (diabetes, hypertension and heart
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failure).114 Strong convergent validity has been established in the MOS-SAS with other
measures of self-care maintenance, self-care management and self-care confidence in
cardiovascular populations.116
Self-care information needs
Self-care information needs were defined as the content required by an individual
so they can perform self-care.117 Self-care information needs were measured with the
Lung Information Needs Questionnaire (LINQ).117 The LINQ is a 16-item questionnaire
developed to assess self-care information needs and COPD knowledge in patients with
COPD.117 Six domains comprise the LINQ; these include disease knowledge, medicines,
self-management, smoking, diet, and exercise. Item scores for each domain are added to
achieve a range of total scores from 0 to 25, with higher scores indicating higher
information needs. There is no set cutoff for adequacy of informational needs. LINQ total
score has satisfactory internal consistency with a Cronbach’s α of 0.62.117 Test-retest
reliability for the total score was good (0.89) and for the six subscales, coefficients
ranged from 0.66 to 0.98.117 A series of focus groups that included patients with COPD
and expert healthcare providers supported the content validity of the LINQ in measuring
information needs in patients with COPD.117
Intervention
The educational intervention contained seven self-guided modules (Table 1.)
These modules included nutrition and diet, physical activity and exercise, medications,
breathing control, mental health, environment, and exacerbation planning. The
educational modules contained material written at a fifth-grade reading level, and
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imbedded videos. Information included in each module was derived from current selfcare research evidence, 13-15,21,88,118-120 as well as current clinical guidelines from
organizations that included the Global Initiative for Obstructive Lung Disease (GOLD),4
American Lung Association,121,122 American Thoracic Society,123 and COPD
Foundation.124,125 All information was appropriate for individuals at any level of self-care
proficiency. The educational intervention was housed on a password-protected webpage
accessible via the study website, accessed by participants using a tablet computer.
Participants were sent a text message containing a password to access the educational
intervention eight days after completion of the baseline measures.
Text messaging to promote adherence
Participants also received daily text messages from the investigator (Days 2- 21).
The text messages were sent between 1600 and 1900 every day, to remind the participant
to complete their daily measures. Each text message was sent individually to maintain
patient confidentially. Text messages were designed based upon the transtheoretical
model of Prochaska and colleagues;126 specifically two experiential processes of change
were targeted, consciousness raising and dramatic relief. Moreover, the text messages
were targeted and tailored to each participant as outlined by Noar and Harrington.127 Text
messages were tailored to reinforce targeted behaviors.
Procedure
Recruitment and enrollment
The Baptist Health Lexington and University of Kentucky Medical Institutional
Review Boards approved this study. Eligible patients were approached by the principal
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investigator who introduced himself and explained the purpose of the visit upon
conclusion of the interaction with their pulmonologist. Before enrollment, potential
participants were screened for mild cognitive impairment using the Mini-Cog©128 and for
adequate health literacy using the Newest Vital Sign.129 Upon determination of adequate
health literacy and absence of cognitive impairment, potential participants were asked
whether they had in-home Wi-Fi and a cell-phone with text messaging capabilities. After
enrollment, participants were provided with and trained in the use of a tablet-computer
(Amazon Fire Tablet, 8 gigabytes, 7th generation); training included how to change
settings (power on/off, volume, charging, accessibility display, Wi-Fi connection), how
to access and complete a daily symptom diary, how to access the intervention education
materials, and how to access and complete the other required instruments. Each
participant was also given written instructions and reminders about when and how to
access the components of the intervention, and how to contact the principal investigator if
problems occurred. The tablet-computer was fully unlocked and pre-loaded with a link to
the website with the intervention.
Baseline data collection took place in an empty exam room. All measures (Day 1
– 21) were completed wirelessly using an encrypted data collection system (Research
Electronic DataCapture [REDCap]), housed behind a firewall at the University of
Kentucky. Participants were given instructions to connect their tablet computer to their
home Wi-Fi to ensure accessibility to the website. All data were automatically
transmitted to REDCap upon completion of each instrument.
Baseline measures
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Baseline measures were obtained for symptom severity (DDS for distress due to
cough, chest tightness, distress due to mucous, dyspnea with activity, dyspnea at rest, and
fatigue), anxiety and depressive symptoms (HADS), perceived self-care ability (SMASS), perceived self-care adherence (MOS-SAS) and self-care information needs
(knowledge; LINQ). Participants completed the measures independently or with the help
of their caregiver; the PI was present for assistance in using the tablet.
Daily Measures
Participants were asked to complete a daily symptom diary for the next 20
consecutive days (Table 2.), at a time of their choosing using the tablet-computer. On the
website, there was a dedicated daily symptom diary section that contained separate links
to each respective daily symptom diary. Participants were also informed that there would
be additional measures of anxiety, depressive symptoms and perceived self-care ability
on Days 8 and 15; at the end of the study (Day 21) participants repeated all measures.
Data management
Data files were assessed for missing data points and evaluation of data
distributions in preparation for analysis. Data were screened using frequency distributions
to evaluate the degree of missing data and the presence of outliers. Missing data were not
imputed and were left missing. Outliers and leverage points were left unadjusted.
Data analysis
Descriptive statistics including means (standard deviations) and frequencies
(percent) were used to characterize the sample. Symptom severity was determined for
each symptom by calculating the mean of symptom ratings pre-intervention, during the
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intervention period, and across the entire 21-day reporting period for each participant.
Participants were then categorized into tertiles of low (n = 7), medium (n = 6) or high
severity (n = 7) for each symptom, based upon the pre-intervention mean (day 1 – 7).
Symptom variability was determined by calculating the standard deviation of symptom
ratings pre-intervention, during the intervention period, and across the 21-day reporting
period for each participant. Based upon the standard deviations calculated in the preintervention period, patients were then categorized into tertiles of low (n = 7), medium (n
= 6) or high variability (n = 7) for each symptom.
To determine the effect of the intervention on symptom severity and variability,
multilevel growth models (MGMs) were constructed using the fixed effects of symptom
severity group (low, medium high), symptom variability group (low, medium, high),
intervention status (pre-intervention [Day 1-7] or intervention period [Day 8 – 21]),
symptom severity group by intervention status, and symptom variability group by
intervention status; each participant was modeled as a random effect with random
intercepts and random slopes, using an identity covariance structure, and all estimations
were made using maximum likelihood estimation. Each growth model was constructed to
examine symptom severity (distress due to cough, chest tightness, distress due to mucous,
dyspnea with activity, dyspnea with rest, and fatigue) as a function of time; time was
centered on zero (Days 0-20). To determine the best fitting model for predicting change
in symptom severity, a sensitivity analysis analyzing the -2Log Likelihood (-2LL) was
conducted. Two MGMs were constructed and compared for each symptom; in the first
model, symptom severity group (low, medium, high) and symptom severity group by
intervention status were imputed as factors; in the second model, symptom variability
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group (low, medium, high) and symptom variability group by intervention status were
imputed as factors.
To examine the consistency of symptom variability between the pre-intervention
and intervention periods, a series of McNemar tests were conducted. Symptom variability
was determined by calculating the standard deviation of symptom scores for each
symptom, during the pre-intervention period and intervention period; based on the
standard deviations, participants were placed into low or high symptom variability
groups. The median standard deviation for each symptom in the pre-intervention period
was used as a reference point to categorize participants into either high or low variability.
For each symptom, 10 participants were in each category for the pre-intervention period.
Then, standard deviations were calculated for the intervention period; values were
assessed using the median standard deviation from the pre-intervention period. Using the
median value from the pre-intervention period, participants were then categorized as low
or high variability for the intervention period. By using the pre-intervention median value
as a reference point, participants could be evaluated for improvement or worsening of
standard deviation values for each time period.
To further examine the effects of the intervention, three repeated measures
ANOVAs (RM-ANOVA) were conducted to compare mean scores for anxiety,
depressive symptoms and perceived self-management ability at baseline to measures
collected on, Day 7, Day 15 and Day 21. Paired sample t-tests were conducted to
compare mean perceived self-care adherence and perceived self-care information needs
scores between pre and post intervention. All analyses were performed using SPSS
version 24 (IBM, Armonk, NY) with an a priori α = 0.05 to indicate significance.
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RESULTS
Characteristics of the participants
A total of 133 patients were screened for eligibility (Figure 1.). Thirty-seven
patients met eligibility criteria and were screened for cognitive function and health
literacy; 17 were excluded. Nine patients were excluded for mild cognitive impairment, 5
were excluded for inadequate health literacy, 2 were excluded due to an inability to use
the tablet, and 1 declined the invitation.
Participants (n = 20) in this study were primarily female (65%), obese (mean BMI
30.2 + 7.6) Caucasian (90%), and on average 62 + 7 years of age (Table 3.). A majority
of participants had at least a high school education (60%), were single, widowed, or
divorced (65%), and were not working due to disability, retirement or lack of
employment (60%). A majority of the participants were categorized GOLD stage III/IV
(55%); the mean % predicted FEV1 was 43 + 15%. On average, participants reported 1.5
+ 1.2 exacerbations requiring hospitalization in the prior year. Eight participants (40%)
reported they were current smokers, while 50% of participants had quit smoking at some
point. On average, participants had 6.6 + 4.6 comorbidities and were prescribed 12.9 +
6.6 daily medications. Participants submitted 401 (95.5%) daily symptom diaries.
Fourteen participants (74%) completed 100% of their daily diaries. Six participants
contacted the investigator with issues using the tablet or website. One participant was lost
to follow up on Day 11 due to an exacerbation requiring hospitalization.
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Symptom severity and variability
Symptoms were measured daily by participants for 21 days using a 0 to 100 VAS
(Table 2.). At baseline, score for distress due to cough averaged 26.6 + 25.4, for chest
tightness 28.8 + 24.1, distress due to mucous 27.9 + 22.3, for dyspnea with activity 45.4
+ 27.8, for dyspnea at rest 25.8 + 26.1, and fatigue 38 + 26.8. Paired sample t-tests were
used to compare mean values between baseline and intervention scores. There were no
significant differences in means between the two time periods for the six symptoms.
To determine whether symptom severity group or symptom variability group
were predictors of symptom scores over time, we conducted a sensitivity analysis for
each MGM. Results from sensitivity analyses revealed that symptom group severity and
the interaction term of symptom group severity by intervention status produced lower
-2LL statistics for all six symptoms; thus, all reported MGM results hereafter reflect the
effects of symptom severity group. MGM analyses determined there was no significant
effect of the intervention on average symptom severity for any of the six symptoms (p =
.08 – 0.97). However, there were significant interactions of severity group by intervention
status for distress due to cough, chest tightness, dyspnea with activity, and fatigue (Table
4; Figure 2.). Those who were in the medium tertile for distress due to cough at baseline
demonstrated an increase in reported distress due to cough after the intervention (b =
10.16, 95% confidence interval [CI] 1.95 – 18.40, t(83) = 2.46, p = .02) compared to
those in the other two tertiles. Individuals in the medium tertile for severity of chest
tightness at baseline reported significantly worse severity after the intervention (b = 8.47,
t[103] = 2.06, p = .04); while those in the high tertile reported significantly lower severity
of chest tightness after the intervention (b = -8.15, t[113] = -2.03, p = .04). Dyspnea with
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activity in the medium tertile increased after the intervention (b = 13.18, t[82] = 1.97, p =
.05). Those who were in the medium tertile for fatigue at baseline also reported a
significant increase in distress (b = 16.48, t[134] = 3.89, p < .01) compared to the low or
high tertile.
A series of McNemar tests was conducted to examine the consistency between the
number of participants in high or low variability group between the pre-intervention and
intervention periods (Table 5.). There were no significant differences in proportion of
participants categorized as high or low symptom variability from the pre-intervention
period to the intervention period.
Comparison of anxiety, depressive symptoms, and perceived self-care ability
Anxiety, depressive symptoms, and perceived self-care ability scores were
measured four times (baseline, Day 8, 15 and 21) and compared with RM-ANOVA
(Table 6.). At baseline, anxiety scores averaged 6.6 + 3.3, depressive symptoms 5.6 + 3.5,
and perceived self-care ability averaged 58.9 + 12. There were no significant differences
in scores among the measurement times (p = .62; p = .66; p = .07, respectively).
Comparison of self-care adherence and self-care information needs
Perceived self-care adherence and perceived self-care information needs were
measured at baseline and on Day 21 after completion of the intervention. Baseline mean
scores were compared to scores obtained on Day 21 with paired t-tests. Perceived selfcare adherence scores increased significantly post intervention (baseline - 58.1 + 19.3,
post intervention - 67.6 + 12.2, p = .025). Perceived self-care information needs were
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significantly reduced after the intervention (baseline - 13.7 + 3.1, post intervention - 11.3
+ 1.8, p = .012).
DISCUSSION
We tested the use an eHealth educational intervention for patients with COPD and
evaluated its effect on symptom reporting, perceived anxiety and depressive symptoms,
perceived self-care ability, adherence and needed knowledge. Symptom scores reported
during the pre-intervention time period were of low to moderate severity, indicating that
symptom burden for these participants was relatively modest. The most burdensome
symptom was dyspnea with activity, which is common for participants with moderate to
severe disease state. Participants in the middle tertile of reported symptom severity at
baseline perceived that certain symptoms (distress due to cough, chest tightness, dyspnea
with activity and fatigue) were more severe after the intervention. Those in the highest
tertile for chest tightness severity reported less burdensome distress during the
intervention period. There were no significant changes in anxiety, depressive symptoms,
or perceived self-care ability after the intervention. However, perceived self-care
adherence scores significantly improved, and self-care information needs were
significantly reduced after the intervention.
Our participants interacted with the intervention and were adherent to completion
of the study instruments. This level of interaction was consistent with previous
investigators who tested an eHealth intervention and used tailored text messaging to
promote adherence; adherence to daily symptom diaries and/or intervention activities
have been reported to be as high as 92% to 99%. 130-132 The engagement of our
participants with the study may be attributed to a number of factors. First, the daily
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tailored and targeted text messages were sent to participants to promote completion of
daily diaries; previous investigators have shown that targeted and tailored text messaged
aimed to promote desired behaviors resulted in higher completion rates in studies
assessing adherence in chronic illness.133,134 Second, the participants included in this
sample were a non-probability sample; thus, they were willing to participate and engage
upon enrollment. Third, the intervention was built to be engaging by using plain,
understandable language that was applicable to patients at any level of self-care
proficiency, and information was presented with a variety of different mediums (text,
pictures, and videos) to prevent boredom with the intervention. Thus, it is plausible these
strategies were successful.
Using baseline symptom severity measures, participants were placed in tertiles
that represented low, medium and high severity of each symptom. Multilevel growth
models were constructed using the symptom severity group (low, medium high),
intervention status (pre-intervention [Day 1-7] or intervention [Day 8 – 21]), and the
interaction term of symptom severity group by intervention status as factors. We found
several significant interactions between symptom severity group and the intervention,
which indicated the effect of the intervention was dependent on the severity group. Those
participants who were in the low symptom severity tertile at baseline reported no
significant changes in perceived symptoms over the 21-day reporting period. Participants
in the medium tertile group, reported a significant increase in severity of distress due to
cough (p = .02), chest tightness (p = .04), dyspnea with activity (p = .05), and fatigue (p <
.01). Participants in the high severity tertile for chest tightness (p = .04) reported a
significant reduction in this symptom over time. Those participants in the medium
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severity tertile likely became more aware of their daily symptoms using the daily diary;
thus, the educational intervention may have helped them evaluate their symptoms
differently, potentially more accurately. Those participants in the high severity tertile for
chest tightness reported a less severe symptom during the intervention period; thus,
participants determined that their distress due to chest tightness was reduced after the
intervention. Participants either experienced reduced symptom severity or the educational
intervention altered their evaluation of this symptom. Also, symptoms determined to be
maximal can only improve. Thus, the change in symptom evaluation was dependent on
their baseline severity perception of symptoms.
Previous investigators have examined the effects of a self-care interventions on
symptom burden over the course of 3, 6 and 12 month follow-up periods.87,120,135 In a
recent meta-analysis of studies about the effects of self-care interventions on outcomes,
the investigators concluded that self-care interventions decreased symptom burden by
6.6% on average.87 However, in a number of the trials included in this meta-analysis, the
investigators determined that symptom burden remained unchanged or increased after
implementation of a self-care intervention.136-139 Bourbeau137 and Monninkhof136 found
no changes in symptom burden at 4 and 12-month follow up. Taylor and colleagues139
found an increase in symptom burden by 4.7% at six month follow up; McGeoch and
colleagues found an increase in symptom burden by 4.7% at 12 months post
intervention.138 These investigators proposed several explanations for this. First, the
intervention potentially raised awareness of the individual to disease-related symptom
perception; thus, the reported symptom severity increased over time.138,139 Second, the
observed symptom severity in previous studies was low to moderate at baseline; this may
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have limited the ability to detect minute changes in symptoms over time.138 Third, the
intervention tested may have been ineffective at changing symptom perception.136-139
140,141

It is possible that the intervention in these studies did not affect symptom severity,

and reported symptom severity remained unchanged or increased naturally over time.
Moreover, the measures used may not have been sensitive enough to detect a small
degree of change in symptoms. Previous investigators have concluded that the severity
and variability of reported symptom burden varied from 10% to 20%,142,143 which
indicated that patients may have difficulty conceptualizing symptom experience as a
number. These investigators also reported symptoms like pain were easier for patients to
conceptualize as a number when compared to others like fatigue; investigators also
suggested that patients may not regularly quantify some symptoms making perception of
a symptom score difficult and insensitive to small changes.142,143
We proposed that the participants in the middle tertile experienced an increase in
symptom burden (distress due to cough, chest tightness, dyspnea with activity and
fatigue) due to a combination of an increased focus on symptom perception, and the
educational content about symptom monitoring. Previous investigators13,16,144 have
hypothesized that regular monitoring of symptoms increased perception and sensitivity to
symptom change and resulted in participants actualizing their symptoms more accurately.
In our educational intervention, participants were provided education to aid in identifying
each symptom, and to evaluate the severity at that time; this may have resulted in an
increased somatic awareness, with more sensitive symptom recognition, evaluation, and
interpretation. There is also evidence to suggest that those with more severe disease
might be less sensitive to change in symptom severity, and these individuals might be
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worse at performing self-management behaviors, such as responding to changes in
symptom severity.140,144 Bringsvor and colleagues140 proposed that as participant
symptom burden increased, they reported fewer health-directed behaviors (i.e. symptom
monitoring, physical activity, relaxation), which then may have negatively influenced
symptom burden and severity. Previous investigators have examined patient ability to
recall daily symptoms throughout any given day, day to day or weekly.142,145
Investigators found that patient report of average symptom experience over a week were
not as precise as measures of symptom experiences made at their lowest (least
burdensome) or highest (most burdensome) time point.143 Thus, more frequent evaluation
may be more precise. In our study, patients in the medium tertile experienced the greatest
symptom change over time and with daily evaluations were more aware of these changes.
Our participants in the low and high symptom severity tertiles likely had more consistent
symptom experiences. However, further studies are necessary to examine the relationship
between symptom severity and symptom perception in patients with COPD.
On average, our participants did not meet the HADS cut points for presence of
anxiety and depressive symptoms. There were no significant changes in anxiety and
depressive symptom scores between baseline measures and those made on 8, 15 or 21.
We hypothesized that there would be a decrease in the anxiety scores and decrease or no
change in depression scores after the intervention. However, our results did not support
our hypothesis. Some previous investigators also found that self-care interventions had no
effect on anxiety and depression;92-94 while other investigators reported improvement in
anxiety and depression scores after an intervention.89,146,147 Investigators who found no
improvement generally studied participants with low anxiety and depression scores;
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anxiety and depression subscale scores on average were less than 5.5 for the HADS
subscales in these participants.92-94 However, those investigators who reported
improvement in anxiety and depression scores studied participants whose anxiety and
depressive symptoms scores indicated more severe symptoms.146,147,89 Thus, self-care
interventions improved anxiety and depression scores when participants were actually
anxious and had depressive symptoms. Our participants did not report a significant
degree of anxiety and depressive symptoms at baseline; thus, there was no improvement.
Clearly, the initial degree of mental distress will influence the degree of change possible.
At baseline, our participants reported a moderate to high level of perceived selfcare ability. We recruited a convenience sample of patients from a local pulmonary
clinic. It is likely that those who were interested in and volunteered for participation in
this study were already engaged in self-care activities to some degree. A majority of our
participants completed more than a high school education, and we screened for adequate
health literacy and satisfactory cognitive function; thus, our participants may not
represent the typical patient with COPD.
The lack of change in perceived self-care ability could be due to the short time
period of the study or a lack of sensitivity of the SMAS-S to small change. Selfmanagement abilities comprise a set of skills that are meant to be practiced, used and
perfected over time; thus, self-care ability might continue to improve over time and not
be reflected in these initial scores. A number of prior studies measured indices of selfcare ability such as keeping follow up appointments, completing daily symptom diaries,
taking prescribed medications, monitoring for changes in symptoms and contacting
providers for suspected exacerbations.148-150 Investigators for these studies reported no
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change or a gradual decline of adherence to taking medications as prescribed, smoking
habits or cessation, attending pulmonary rehabilitation, and reporting increasing symptom
severity to practitioners.148-150 Researchers postulated that this decline in self-care
behaviors could be due to a loss of interest in self-care, increased complexity in
prescribed treatment regimen, and poor quality of care from providers.24,149 Additionally,
Cramm and Nieboer 151 reported that higher perceived quality of care from providers and
productive patient-professional interactions were significant predictors of higher
perceived self-care ability scores in patients with COPD. However, previous investigators
who examined self-care ability implemented a high dose of their intervention through
repeated, structured interventions over the course of days to weeks; while we designed
our intervention to be less structured and as a smaller dose. Thus, it is likely that our short
time frame and low dose were not adequate to produce change. It is also possible that
since perceived self-care ability was already moderately high in our participants, it is
likely the intervention did not provide a dose adequate to produce an improvement and a
probable ceiling effect was observed.
Our participants did demonstrate significant improvement in perceived self-care
adherence and reduction in perceived self-care information needs. On average, our
participants improved their perceived self-care adherence by 9.5% and reduced their
perceived self-care information needs by 9.6% after the two-week intervention period.
This is consistent with previous investigators who examined the impact of self-care
interventions on adherence and self-care knowledge.152,153 Leiva-Fernandeza and
colleagues152 tested a multidimensional self-care intervention and demonstrated that the
experimental group improved perceived adherence by 30.5% compared to control. Smit
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and colleagues,153 assessed treatment adherence to smoking cessation behaviors (a
component of self-care); participants were 85% to 99% more likely to abstain from
smoking at one week and at 6 month follow up. Although the length of our intervention
was brief (two weeks), we observed improvement in perceived self-care adherence and
reduction in self-care information needs. Results from prior studies indicated that
multidimensional self-care interventions were effective at improving treatment
adherence, reduced perceived information needs, and led to sustained behavior change in
patients with COPD.152,153 Our study is similar to previous investigators in that we
implemented a multifaceted and tailored intervention. However, we used an eHealth
mode of delivery. Our results supported this strategy and demonstrated that participants
actively engaged, learned and increased perceived adherence to self-care behaviors with a
remote, electronic intervention that required minimal provider assistance. Future studies
are needed to examine the long-term impact of self-care adherence and information needs
using eHealth educational interventions in patients with COPD.
Limitations
There are several limitations of this study. The sample for this study was small
and limited power to detect differences for some of our analyses. Although we were
adequately powered for our MGM analyses, the measures may not have had sufficient
sensitivity to detect change. This was a non-probability sample of relatively well
educated participants with adequate health literacy and normal cognitive function.
Second, self-report instruments were used in this study, which introduced the potential
for social desirability and response bias. However, the variables we measured were
subjective; thus, self-report was the only appropriate way to measure them.154 Third, the
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intervention exposure was of short duration because this was the initial step in the
evaluation of dose response to this intervention. In addition, our participants did not
report anxiety or depressive symptoms using the HADS. This instrument might not have
been sensitive in this group of individuals; however, the HADs has been used in other
samples of patients with COPD.89,93-95,146,147 Also, our sample of participants had a high
level of perceived self-care ability; thus, we were unable to determine whether the
intervention can produce a change in people with low perceived self-care ability.
Conclusion
These participants had a low to moderate degree of symptom burden; dyspnea
with exertion was the symptom with greatest severity. Our theory-based, self-care
educational intervention delivery via electronic platform produced change in perception
of distress due to cough, chest tightness, dyspnea with activity and fatigue in participants
with a moderate degree of symptom burden; for those with high symptom burden for
chest tightness, there was a significant decrease in reported symptom. The intervention
produced an improvement in perceived self-care by nearly 10% and reduced perceived
knowledge needs by almost 10%; thus, further testing of this intervention is supported.
This study served as a preliminary study to support that patients with moderate to severe
COPD have the ability to routinely record their symptoms remotely and participate in
self-guided self-care education modules.
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Table 4.1. Description of the seven educational components included in the
intervention
Self-Care

Primary Content Covered

Component

Delivery/
Teaching
Style Used

Nutrition/Diet

1. Caloric intake and weight management

Print,

2. Macronutrients

Pictures,

3. Meal timing and portions

Informational

4. Water consumption

Videos,

5. Vitamins, minerals, and dietary
supplements
Physical

1. Physical activity promotion

Print,

Activity and

2. Recommended exercises for people

Pictures,

Exercise

with COPD

Videos,

3. Amount of exercise per day/week

Interactive

4. Breathing control while exercising

Videos

5. Developing prolonged exercise habits
Medications

1. Compiling an accurate list of
medications

Print,
Pictures,

2. Knowing the timing and dosing of daily
medications

Videos,
Interactive

3. Pharmacological and nonpharmacologic ways to manage acute
symptom onset
4. Establishing the most common side
effects of different medications
5. Establishing an action plan for when
symptoms need acute treatment
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Videos

Table 4.1, Cont.
Breathing

1. Pursed lip breathing

Print,

Control

2. Diaphragmatic/belly breathing

Pictures,

3. Utilizing rest to prevent dyspnea

Videos,

4. Postural positioning for optimal

Interactive

breathing

Videos

5. Using relaxation techniques to combat
the anxiety-dyspnea cycle
Mental Health

1. Identification of life stressors

Print,

2. Developing a plan to combat common

Pictures,

life stressors
3. Utilization of breathing techniques to
reduce anxiety/dyspnea

Videos,
Interactive
Videos

4. Non-traditional ways to cope with
anxiety: meditation, mindfulness, muscle
relaxation, biofeedback, and distraction
therapy
5. Identifying anxiety and depressive
symptoms
Environmental
Modification

1. Smoking cessation/avoiding lung
irritants

Print,
Pictures,

2. Involvement of caregiver/significant

Videos

other/friend/family with medical care
3. Promoting social interaction
4. Energy conservation
5. Modifying living arrangements
Exacerbation

1. Developing an action plan

Print and

Planning

2. Establishing symptom norms and

Pictures

knowing when to seek help
3. Identifying where is most appropriate to
seek medical treatment
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4. Identifying early warning signs of
worsening symptoms
5. Medication uses when symptoms become
worse
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Table 4.2. Timing of variable measurements
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Table 4.3 Characteristics of participants
Characteristic

Total Sample
N = 20

Age in years

62 + 7

Female

13 (65%)

Ethnicity
Caucasian

18 (90%)

Highest Education Level
Less than high school

8 (40%)

High School Graduate or above

12 (60%)

Marital Status
Single

8 (40%)

Married

7 (35%)

Widowed/Divorced

5 (25%)

Smoking Status
Current Smoker

8 (40%)

Quit Smoking

10 (50%)

Never Smoker

2 (10%)

Employment Status
Employed

8 (40%)

Disabled/Sick Leave

6 (30%)

Retired/ Unemployed

6 (30%)

Live Alone

6 (30%)

GOLD Stage
II

9 (45%)

III

5 (25%)

IV

6 (30%)

BMI in kg/m2

30.2 + 7.6

Number of Comorbidities

6.6 + 4.6
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Table 4.3, Cont.
Number of Exacerbations in

1.5 + 1.2

Previous Year
Number of Medications Prescribed

12.9 + 6.6

FEV1 in liters per second

1.17 + .43

% predicted FEV1

43 + 14.9

FVC in liters

2.5 + .73

FEV1/FVC

48 + 13.4

Values are mean + SD or f (%)
Abbreviations: GOLD, Global Initiative for Obstructive Lung
Disease Stage; BMI, body mass index; FEV1, forced expiratory
volume in one second; FVC, forced vital capacity
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Table 4.4. Comparison of symptom severity at baseline with intervention values by
tertiles
Symptom Severity

Mean severity rating

Mean severity

Group

pre-intervention (Day 0

rating intervention

– 6)

(Day 7 – 20)

M + SE

M + SE

P value

Distress due to Cough a
Low 7.16 + 3.13

6.90 + 2.97

.82

Medium 29.96 + 4.93

40.03 + 4.70

.02

High 63.76 + 4.02

60.71 + 3.90

.24

11.79 + 4.55

.15

Medium 33.44 + 4.36

33.12 + 4.13

.79

High 55.84 + 5.28

55.51 + 5.26

.76

Low 7.42 + 3.36

6.40 + 3.13

.43

Medium 35.41 + 4.50

43.30 + 4.20

.04

High 60.48 + 4.10

52.37 + 3.92

.05

9.71 + 3.91

.74

Medium 51.18 + 5.23

63.96 + 4.79

.05

High 66.64 + 3.29

66.95 + 3.07

.95

Low 5.84 + 3.14

9.47 + 2.96

.10

Medium 38.02 + 3.74

39.98 + 3.53

.42

High 73.52 + 5.71

68.07 + 5.65

.93

Low 9.32 + 4.52

15.93 + 4.06

.06

Medium 40.12 + 4.46

56.64 + 4.17

< .01

High 70.24 + 4.82

66.70 + 4.38

.30

Distress due to Mucous b
Low 7.46 + 4.79

Chest Tightness c

Dyspnea with activity d
Low 8.92 + 4.28

Dyspnea with rest e

Fatigue f
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Analyses based on primary outcome variable (symptom severity scores [range 0 – 100]
aFixed

effects: intervention status F(1,383.34) = 3.03, p = .08; severity group

F(2,20.44) = 67.35, p < .01; intervention status*severity group F(2, 383.38) = 7.71, p <
.01;
bFixed

effects: intervention status F(1,380.75) = 1.09, p = .34; severity group

F(2,20.23) = 23.30, p < .01; intervention status*severity group F(2, 381.66) = . 62, p =
.43;
cFixed

effects: intervention status F(1,384.24) = 0.08, p = .78; severity group

F(2,20.66) = 55.14, p < .01; intervention status*severity group F(2, 384.07) = 8.71, p <
.01;
dFixed

effects: intervention status F(1,382.63) = 7.08, p < .01; severity group

F(2,20.82) = 73.35, p < .01; intervention status*severity group F(2, 382.93) = 4.62, p =
.01;
eFixed

effects: intervention status F(1,388.54) = .01, p = .97; severity group F(2,20.26)

= 61.05, p < .01; intervention status*severity group F(2, 385.84) = 2.43, p = .09;
fFixed

effects: intervention status F(1,384.47) = 10.90, p < .01; severity group

F(2,20.87) = 48.26, p < .01; intervention status*severity group F(2, 384.45) = 8.37, p <
.01
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Table 4.5. Comparison of symptom variability at baseline and intervention
Symptom

Pre-Intervention

Intervention

P value

Period
Distress due to Cough

10 (50%)

10 (50%)

1.00

Distress due to Mucous

10 (50%)

6 (30%)

.22

Chest Tightness

10 (50%)

5 (25%)

.13

Dyspnea with Activity

10 (50%)

6 (30%)

.22

Dyspnea with Rest

10 (50%)

12 (60%)

.69

Fatigue

10 (50%)

6 (30%)

.22

Values are frequency (%)
The proportion of participants in the high symptom variability category preintervention were compared to the intervention period using McNemar tests.
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Table 4.6. Comparison of mean scores for symptoms, anxiety, depressive symptoms,
perceived self-care ability, adherence and information needs (n = 19)
Variable
HADS - anxiety
[0 – 21]
HADS –
depression [0 – 21]

P

Baseline

Day 8

Day 15

Day 21

6.6 + 3.3

6.8 + 3.9

6.2 + 4.1

6.3 + 4.3

.62

5.6 + 3.5

5.8 + 3.1

5.5 + 3.3

6.1 + 3.4

.66

58.9 + 12

55.5 + 13.5

54.3 + 14.5

57.4 + 14.5

.07

58.1 + 19.3

-

-

67.6 + 12.2

.03

13.7 + 3.1

-

-

11.3 + 1.8

.01

Value

Perceived Selfcare Ability
(SMAS-18) [12 –
84]
Self-care
Adherence [0 –
100]
Self-care
Information Needs
[0 – 25]
Symptom variable
Distress Due to
Cough
Chest Tightness
Distress due to
Phlegm
Dyspnea with
Activity
Dyspnea at Rest
Fatigue

Pre-intervention period

Intervention-period

26.6 + 25.4

27.8 + 26.2

.59

28.8 + 24.1

28.1 + 24.4

.79

27.9 + 22.3

29.3 + 23.3

.68

45.4 + 27.8

48 + 28.9

.27

25.8 + 26.1

27.4 + 24.3

.48

38 + 26.8

44.8 + 27.2

.08

Values are mean + SD; bracketed information [] are ranges of total possible scores
Comparisons were performed with paired t-tests, or repeated measures analysis of
variance, based on the number of repeated measures.
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Table 4.6, Cont.
Abbreviations: HADS, Hospital Anxiety and Depression Scale; SMAS-18, Selfmanagement Ability Scale – 18-item version
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Figure 4.1. Screening and Enrollment Flow Diagram
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Figure 4.2. Trends in symptom severity over time, stratified by symptom severity
group (low, medium, high).
Distress due to Mucous

Distress due to Cough
p = .82

p = .15

p = .02

p = .79

p = .24

p = .76

Chest Tightness

Dyspnea with Activity
p = .74

p = .43

p = .04

p = .05

p = .05

p = .95

Dyspnea with Rest

Fatigue

p = .10
p = .06

p = .42

p = .01

p = .30

p = .93
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CHAPTER FIVE
Conclusions
Summary of findings
The purpose of this dissertation was to evaluate the relationship between
biological, psychosocial and behavioral self-care attributes and outcomes in individuals
with COPD. COPD affects millions of people worldwide, and as COPD progresses,
symptoms become more severe, physical and psychological responses are elicited, and
risk for hospitalization increases.1 As the prevalence and burden of COPD increases,
patients are taught and expected to perform a variety of self-care activities to maintain
physical, mental, and psychosocial homeostasis. Although research evidence exists to
support the effectiveness of self-care in the reduction of the risk for hospitalization,
increase in health-related quality of life, and significant decreases in symptoms such as
dyspnea, anxiety and depressive symptoms,15,18,21,88 the relationship between self-care
behaviors, symptom burden and perceived self-care ability remain unclear.
The first manuscript was a report of a secondary data analysis in which we
explored the predictive power of forced vital capacity (FVC), forced expiratory volume
in one second (FEV1), and the ratio between the two (FEV1/FVC) for event-free survival
in patients with heart failure and airflow limitation. The second manuscript was a report
of a psychometric evaluation of the Multidimensional Scale of Perceived Social Support
(MSPSS) in a sample of patients with comorbid COPD and heart failure. The third
manuscript reported the testing of a self-care educational intervention using an eHealth
platform, in which symptoms, anxiety, depressive symptoms, perceived self-care ability,
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perceive self-care adherence and self-care information needs (knowledge) were evaluated
before and after the intervention.
Patients with comorbid COPD and heart failure share numerous commonalities
including predisposing risk factors, symptom presentation, and periodic disease
exacerbations. Approximately one-third to 40% of patients diagnosed with heart failure
are also diagnosed COPD.30,31 Although airflow limitation may be present in a significant
proportion of patients with heart failure, the relationship between airflow limitation and
combined all-cause hospitalization/mortality had not been explored in patients with heart
failure and suspected airflow limitation. In the second chapter, we presented a secondary
data analysis examining the predictive power of spirometry measures (forced vital
capacity [FVC], forced expiratory volume in one second [FEV1], and the ratio between
the two [FEV1/FVC]) for event free survival in patients with a primary diagnosis of heart
failure. Airflow limitation resulted in a 2.2 times greater risk of hospitalization or death
compared to those patients without airflow limitation. Individuals who were in NYHA
functional class III/IV were 73% more likely to be hospitalized or die compared to those
with less severe disease (NYHA functional class I/II), and patients who had never
smoked were 62% less likely to have a health-related hospitalization/death. Regularly
measuring airflow limitation in patients with comorbid heart failure and COPD may
permit more effective management and provide an opportunity to reduce
hospitalization/mortality in these patients. Future research studies should focus on the
development and testing of tailored self-care strategies for individuals with comorbid
diseases.
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Due to the high symptom burden, complex treatment regimens, and decrease in
functional capacity, patients with COPD may have caregivers, friends, family or
significant others assist them to manage their disease, symptoms, and prescribed
treatments. Chapter Three contains a report of a psychometric evaluation of the
Multidimensional Scale of Perceived Social Support (MSPSS) in patients with comorbid
COPD and heart failure. The MSPSS was evaluated for internal consistency, split-half
reliability, construct validity with factor analysis, and hypothesis testing. Findings
revealed that in patients with comorbid COPD and heart failure, the MSPSS had excellent
internal consistency, and good split-half reliability. Factor analysis yielded a 3-factor
solution with instrument items loading appropriately on each of the three subscales of the
MSPSS. Hypothesis testing further supported construct validity; perceived social support
scores predicted higher self-care management scores. We concluded the MSPSS was a
valid and reliable instrument to measure perceived social support in patients with
comorbid COPD and heart failure. Further research is warranted to examine the impact of
perceived social support on key outcomes in individuals with COPD and heart failure,
such as symptom burden, anxiety, depression, self-care ability, and survival.
There is a lack of evidence about the immediate effects of self-care interventions
on key outcomes, particularly symptom burden (severity of distress due to cough, chest
tightness, distress due to mucous, dyspnea with activity, dyspnea at rest, fatigue, anxiety,
and depressive symptoms). The third paper in this dissertation reported a test of a theorybased, multidimensional, self-care educational intervention on key outcomes in patients
with COPD. Intervention components included modules about diet, breathing control,
mental health, physical activity, medications, environment modification and
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exacerbations; outcome measures were symptoms (distress due to cough, chest tightness,
distress due to mucous, dyspnea, fatigue, anxiety and depressive symptoms) perceived
self-care ability, and self-care information needs (knowledge). Growth models were
constructed to examine the impact of the intervention on symptom severity and
variability. Repeated measures analysis of variance examined the effect of the
intervention on anxiety and depressive symptoms, and perceived self-care ability at the
end of week 1, 2 and the conclusion of the reporting period. Paired t-tests determined the
effect of the intervention on perceived self-care adherence and self-care information
needs (knowledge). This intervention resulted in significant change in symptom severity
evaluation in patients categorized as having medium symptom severity for distress due to
cough, chest tightness, dyspnea with activity and fatigue; these symptoms were perceived
as more severe in the intervention period. Anxiety, depressive symptoms and perceived
self-care ability were unchanged; however, perceived self-care adherence scores
improved, and knowledge needs were significantly reduced after the intervention.
Our findings described the immediate impact of a self-care intervention on
symptom evaluation, as well as perceived self-care adherence and self-care information
needs (knowledge). Future studies will provide additional data. First, future studies are
needed to examine the hypothesis that baseline symptom severity has an impact on the
effect of self-care interventions. Second, further exploration is warranted regarding the
effect of tailored self-care interventions on anxiety and depressive symptoms in patient
with COPD. Since our patients were not exhibiting substantial anxiety or depressive
symptoms at baseline, it is difficult to draw conclusions regarding the effects of the
intervention on these outcomes. Third, longitduinal studies with time periods up to one
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year are needed to evaluate the long term effects of self-care interventions on variables
such as symptom burden, self-care adherence and information needs using eHealth
educational interventions in patients with COPD. Furthermore, an increased dose of the
intervention, addition of a control group, and accounting for the time of year (to account
for expected seasonal fluctuations) are warranted.
Impact of dissertation on the state of the science
There are few investigators who have examined the effect of a self-care
intervention on symptoms such as distress due to cough, chest tightness, distress due to
mucous and fatigue in patients with COPD. Although researchers have established that
symptom burden was a significant clinical problems in patients with COPD, self-care
interventions have not been found to improve symptom perception with the exception of
dyspnea, anxiety and depressive symptoms.19,120 Although investigators have tested
interventions to improve self-care in patients with COPD, the most recent American
Thoracic Society and GOLD guidelines for management of stable COPD provided
minimal recommendations for self-care behaviors.4,155 Current recommendations
included taking medications as prescribed, smoking cessation, and reporting increased
symptom severity or potential exacerbations to providers; future research is needed to
establish evidence-based guidelines and recommendations for other aspects of self-care
including, diet/nutrition, mental health, physical activity, and environment modification.
In this dissertation, my research findings have: 1) identified the influence of
comorbid disease (heart failure and COPD) on key outcomes, hospitalization and
survival; 2) tested the psychometric rigor of a measure of perceived social support in
patients with comorbid chronic conditions (COPD and heart failure); 3) concluded
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perceived social support is a significant predictor of perceived self-care management
ability in patients with comorbid COPD and heart failure; 4) demonstrated that an
electronic, educational intervention altered the perception of symptom severity in subsets
of patients and increased self-care adherence and knowledge in patients with COPD; 5)
demonstrated that patients with COPD recorded daily symptom evaluation with high
rates of adherence; 6) supported that this short dose of an intervention improved
perceived self-care adherence and reduced knowledge needs; and 7) demonstrated that
this selected sample of patients with COPD were able to interact with the intervention,
given the short exposure, and received benefit from the intervention.
There are limitations of this dissertation. Two of the three manuscripts reported
retrospective data analyses; thus, we could not control for other variables that may have
influenced the evaluated patient outcomes. These secondary analyses were also limited in
terms of data collected; for the survival analyses, there were limited number of
participants with confirmed spirometry values indicating presence of airflow limitation
and COPD. For the third study, the sample was small and had limited power to detect
differences for some of our analyses. Although we were adequately powered for our
growth curve analyses, the measures may not have had sufficient sensitivity to detect
change. Furthermore, all of the instruments used in this study were self-report, which
introduced the potential for social desirability and response bias. However, the variables
we measured were subjective; thus, self-report is the only suitable way to measure
them.154 Future objective measures of self-care adherence, medication adherence,
physical activity, and nutritional intake should be used to compare actual to perceived
variables.
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Further systematic research studies are needed to determine the most effective
strategies to improve self-care in this population. Future studies should aim to identify
key health behaviors that would promote optimal health for patients with COPD and test
those behaviors for improvements in outcomes. Moreover, subsequent studies should aim
to examine the validity of self-reported symptom burden measures, especially for
symptoms such as distress due to cough, chest tightness, distress due to mucous and
fatigue. Finally, investigators should focus on exploring the short-term and long-term
impact of self-care interventions on symptom burden, anxiety, depression, sustained
adherence, morbidity and mortality.
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